CA2485178A1 - Lactic acid bacteria-derived bacteriocin and uses thereof for prevention or treatment of cancer - Google Patents
Lactic acid bacteria-derived bacteriocin and uses thereof for prevention or treatment of cancer Download PDFInfo
- Publication number
- CA2485178A1 CA2485178A1 CA002485178A CA2485178A CA2485178A1 CA 2485178 A1 CA2485178 A1 CA 2485178A1 CA 002485178 A CA002485178 A CA 002485178A CA 2485178 A CA2485178 A CA 2485178A CA 2485178 A1 CA2485178 A1 CA 2485178A1
- Authority
- CA
- Canada
- Prior art keywords
- bacteriocin
- derived
- spp
- cancer
- pediocin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010062877 Bacteriocins Proteins 0.000 title claims abstract description 191
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 138
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 74
- 241000894006 Bacteria Species 0.000 title claims abstract description 72
- 239000004310 lactic acid Substances 0.000 title claims abstract description 69
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 69
- 201000011510 cancer Diseases 0.000 title claims abstract description 66
- 230000002265 prevention Effects 0.000 title claims description 24
- 238000000034 method Methods 0.000 claims abstract description 100
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 241001465754 Metazoa Species 0.000 claims abstract description 38
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 8
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 230000035755 proliferation Effects 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 100
- 229960000448 lactic acid Drugs 0.000 claims description 66
- 108010049023 pediocin PA-1 Proteins 0.000 claims description 65
- ZRUMXHGBGLWVDT-SJMRFLIKSA-N pediocin pa 1 Chemical compound C([C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@H](CC=2NC=NC=2)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(O)=O)C1=CN=CN1 ZRUMXHGBGLWVDT-SJMRFLIKSA-N 0.000 claims description 64
- 239000003795 chemical substances by application Substances 0.000 claims description 61
- 150000001413 amino acids Chemical group 0.000 claims description 56
- 108010080032 Pediocins Proteins 0.000 claims description 38
- 241000191998 Pediococcus acidilactici Species 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 21
- -1 leucocin Chemical compound 0.000 claims description 20
- 241000192001 Pediococcus Species 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 210000001072 colon Anatomy 0.000 claims description 11
- 235000021107 fermented food Nutrition 0.000 claims description 11
- 241000186660 Lactobacillus Species 0.000 claims description 10
- 108010053775 Nisin Proteins 0.000 claims description 10
- 239000000356 contaminant Substances 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims description 9
- 239000004309 nisin Substances 0.000 claims description 9
- 235000010297 nisin Nutrition 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 210000001165 lymph node Anatomy 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 241000194033 Enterococcus Species 0.000 claims description 7
- 241000194036 Lactococcus Species 0.000 claims description 7
- 241000192132 Leuconostoc Species 0.000 claims description 7
- 241000194017 Streptococcus Species 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 108010042648 lactocin Proteins 0.000 claims description 7
- 108010066097 lactococcin A Proteins 0.000 claims description 7
- XJAJBFWPYSQCKP-UHFFFAOYSA-N methyl 2-(6,7-dimethyl-3-oxo-4h-quinoxalin-2-yl)-4-(4-methoxy-2-nitroanilino)-3,4-dioxobutanoate Chemical compound N=1C2=CC(C)=C(C)C=C2NC(=O)C=1C(C(=O)OC)C(=O)C(=O)NC1=CC=C(OC)C=C1[N+]([O-])=O XJAJBFWPYSQCKP-UHFFFAOYSA-N 0.000 claims description 7
- SUJOIPVTNUVDCB-UHFFFAOYSA-N mutactin Natural products CC1=CC(O)=C2C(=O)CC(O)CC2=C1C1=CC(O)=CC(=O)O1 SUJOIPVTNUVDCB-UHFFFAOYSA-N 0.000 claims description 7
- 108010043542 streptin Proteins 0.000 claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 230000002601 intratumoral effect Effects 0.000 claims description 6
- 210000000278 spinal cord Anatomy 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 210000004100 adrenal gland Anatomy 0.000 claims description 5
- 210000000436 anus Anatomy 0.000 claims description 5
- 210000003679 cervix uteri Anatomy 0.000 claims description 5
- 235000015140 cultured milk Nutrition 0.000 claims description 5
- 210000004696 endometrium Anatomy 0.000 claims description 5
- 210000003238 esophagus Anatomy 0.000 claims description 5
- 210000000232 gallbladder Anatomy 0.000 claims description 5
- 210000002865 immune cell Anatomy 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 210000003101 oviduct Anatomy 0.000 claims description 5
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 230000000849 parathyroid Effects 0.000 claims description 5
- 230000001817 pituitary effect Effects 0.000 claims description 5
- 210000000664 rectum Anatomy 0.000 claims description 5
- 210000004872 soft tissue Anatomy 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 5
- 210000001215 vagina Anatomy 0.000 claims description 5
- 210000003905 vulva Anatomy 0.000 claims description 5
- 210000004180 plasmocyte Anatomy 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 description 60
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 239000000872 buffer Substances 0.000 description 21
- 229920001817 Agar Polymers 0.000 description 19
- 239000008272 agar Substances 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 241000588724 Escherichia coli Species 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 230000001093 anti-cancer Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 9
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 101150026459 pedA gene Proteins 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 7
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 241000235058 Komagataella pastoris Species 0.000 description 7
- 241000191996 Pediococcus pentosaceus Species 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 229940041514 candida albicans extract Drugs 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000012138 yeast extract Substances 0.000 description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- 102100029727 Enteropeptidase Human genes 0.000 description 5
- 108010013369 Enteropeptidase Proteins 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 241000235648 Pichia Species 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000002417 nutraceutical Substances 0.000 description 5
- 235000021436 nutraceutical agent Nutrition 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000012465 retentate Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 108010073254 Colicins Proteins 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010036176 Melitten Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 229920001222 biopolymer Polymers 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 201000005296 lung carcinoma Diseases 0.000 description 4
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 4
- 230000003641 microbiacidal effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000004627 regenerated cellulose Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 108050004290 Cecropin Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- 235000013477 citrulline Nutrition 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 201000010897 colon adenocarcinoma Diseases 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 2
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 2
- SXGMVGOVILIERA-UHFFFAOYSA-N 2,3-diaminobutanoic acid Chemical compound CC(N)C(N)C(O)=O SXGMVGOVILIERA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 2
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 108060003100 Magainin Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 2
- 101100084009 Pediococcus acidilactici pedA gene Proteins 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 102000007238 Transferrin Receptors Human genes 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WTOFYLAWDLQMBZ-LURJTMIESA-N beta(2-thienyl)alanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CS1 WTOFYLAWDLQMBZ-LURJTMIESA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000019249 food preservative Nutrition 0.000 description 2
- 239000005452 food preservative Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- FLTWKHKMXZLDNR-CVMNUACMSA-N pediocin ach Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)NCC(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)OC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1N=CN=C1)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)O)C1C=NC=N1 FLTWKHKMXZLDNR-CVMNUACMSA-N 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- YPJJGMCMOHDOFZ-ZETCQYMHSA-N (2s)-2-(1-benzothiophen-3-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CSC2=C1 YPJJGMCMOHDOFZ-ZETCQYMHSA-N 0.000 description 1
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DEENCNYPFDWDSA-UHFFFAOYSA-N 2-ethyl-1,3-benzothiazole-6-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2SC(CC)=NC2=C1 DEENCNYPFDWDSA-UHFFFAOYSA-N 0.000 description 1
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 241000020089 Atacta Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000000632 Experimental Neoplasms Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000604136 Pediococcus sp. Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241000235061 Pichia sp. Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 108010025955 Pyocins Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000000445 cytocidal effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000014155 detection of activity Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 201000008822 gestational choriocarcinoma Diseases 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- VWHRYODZTDMVSS-QMMMGPOBSA-N m-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(F)=C1 VWHRYODZTDMVSS-QMMMGPOBSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 108010074461 nisin A Proteins 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- POECFFCNUXZPJT-UHFFFAOYSA-M sodium;carbonic acid;hydrogen carbonate Chemical compound [Na+].OC(O)=O.OC([O-])=O POECFFCNUXZPJT-UHFFFAOYSA-M 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/34635—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3571—Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Methods of preventing or treating cancer and of inhibiting proliferation of cancerous cells are disclosed herein. These methods comprise administering to an animal a bacteriocin derived from a lactic acid bacteria and/or a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier. In an embodiment, the bacteriocin may be cytotoxic to the cancerous cells. Also described herein are corresponding uses of these bacteriocins and compositions as well as packages comprising these bacteriocins and compositions.
Description
LACTIC ACID BACTERIA-DERIVED BACTERIOCIN AND USES THEREOF FOR
PREVENTION OR TREATMENT OF CANCER
FIELD OF THE INVENTION
The invention relates to the use of bacteriocins and compositions comprising such bacteriocins for the treatment and/or prevention of cancer. The invention also relates to the use of bacteriocins and compositions comprising such bacteriocins for inhibiting proliferation of cancerous cells. The invention particularly relates to bacteriocins derived from lactic acid bacteria and compositions comprising such bacteriocins.
BACKGROUND OF THE INVENTION
Conventional chemotherapeutic agents are usually not specific towards cancerous cells and halt the progression of any dividing cells. As such, these drugs are highly cytotoxic and can cause serious side effects (loss of hair, loss of intestine villosities, depletion of immune cells, etc.) and can impair significantly the quality of life of the patient (infertility, depression, etc.). Consequently, their use if often limited by the amount one can tolerate.
In addition, the use of conventional chemotherapeutic agents is also known to cause drug resistance in cancerous cells, and often multi-drug resistance. Hence, clinicians have to readjust, over the course of the treatment, the dosage and/or the composition of chemotherapeutic cocktails to take into account the newly acquired drug resistance phenotype of the cancerous cells.
Further, to date, many cancers cannot be treated and represent a significant percentage of mortality.
There is thus a need for improved chemotherapeutic agents. These agents may be more effective, more selective towards cancerous cells, may riot cause drug resistance and/or may be used to halt the progression of multi-drug resistant cancerous cells.
SUI~1ARY OF THE INVENTION
The present invention relates to the use of a bacteriocin, and more particularly to the use of a bacteriocin for the treatment and prevention of cancer.
In a first aspect, the present invention provides a method of preventing or treating cancer in an animal, the method comprising administering to the animal an agent selected from the group consisting of (a) a bacteriocin derived from a lactic-acid bacteria, and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier (or any combinations thereof).
In an embodiment, the agent is cytotoxic to the cancerous cell of the cancer. In another embodiment, the agent is administered through or adapted for administration through a route selected from the group consisting of intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal, intratumoral and topical. In yet another embodiment, the agent is the bacteriocin and, in a further embodiment, the bacteriocin is substantially pure. In another embodiment, the bacteriocin is a recombinant bacteriocin and, in a further embodiment, the recombinant bacteriocin is produced in a prokaryotic host. In yet another embodiment, the bacter_iocin is selected from the group consisting of bavaricin, helveticin, acidocin, lactocin, lactacin, lacticin, nisin, leucocin, lactococcin, pediocin, curvaticin, curvacin, mutacin, mesentericin, plantaricin, streptin and sakacin. In another embodiment, the bacteriocin is pediocin arid, in a further embodiment, the bacteriocin is pediocin PA-1. In yet another embodiment, the pediocin PA-1 comprises an amino acid sequence substantially identical to the sequence set forth in SEQ ID NO: 2 or a fragment thereof. In yet a further embodiment, the bacteriocin is derived from a lactic acid bacteria species selected from the group consisting of Streptococcus spp., Lactococcus spp., Lactobacillus spp., Pediococcus spp., Leuconostoc spp., Bifidobacterium spp. and Enterococcus spp.
In an embodiment, the bacteriocin is derived from Pediococcus spp, in a further embodiment, the bacteriocin is derived from Pediococcus acidilactici and, in yet a further embodiment, the bacteriocin is derived from Pediococcus acidilactici PAC
1Ø
In an embodiment, the agent is the above-mentioned composition. In another embodiment, the carrier is selected from the group consisting of a pharmaceutically acceptable carrier and a nutraceutically acceptable carrier and, in a further embodiment, the carrier is a nutraceutically acceptable carrier. In yet another embodiment, the agent is administered through or adapted for administreation through an oral route. In another embodiment, the composition is substantially free of contaminants from the lactic acid bacteria from which said bacteriocin is derived. In an embodiment, the nutraceutically acceptable carrier is a food product, in a further embodiment, the food product is a fermented food product and, in yet a further embodiment, the fermented food product is a fermented milk. In another embodiment, the animal is a mammal and, in yet a further embodiment, the mammal is a human. In an embodiment, the cancer affects an organ, tissue, cell or system selected from the group consisting of bone, soft tissue, brain, spinal cord, breast, adrenal gland, pancreas, parathyroid, pituitary, thyroid, anus, colon, rectum, esophagus, gallbladder, stomach, liver, cervix, endometrium, uterus, fallopian tube, ovaries, vagina, vulva, larynges, oropharynges, immune cell, immune system, lung, lymph node and plasma cell. In another embodiment, the cancer is lung cancer and/or colon cancer.
In another aspect, the present invention provides use of an agent selected from the group consisting of (a) a bacteriocin derived from a lactic acid bacteria and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier for the prevention or treatment of cancer in an animal. In a further aspect, the present invention provides use of an agent selected from the group consisting of (a) a bacteriocin derived from a lactic acid bacteria and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier for the preparation of a medicament for the prevention or treatment of cancer in an animal. In an embodiment, the agent used is the agent described herein. In yet another embodiment, the animal is the animal described herein. In another embodiment, the cancer treated or prevented is the cancer described herein.
In yet another aspect, the present invention provides a bacteriocin derived from a lactic acid bacteria for use in the prevention or treatment of cancer in an animal.
In still a further aspect, the present invention provides a composition comprising (i) a bacteriocin derived from a lactic acid bacteria and (ii) a carrier for use in the prevention or treatment of cancer in an animal.
In still another aspect, the present invention provides a package comprising (a) an agent selected from the group consisting of (i) a bacteriocin derived from a lactic acid bacteria and (ii) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier and (b) instructions for the use of said agent in the treatment or prevention of cancer in an animal. In an embodiment, the agent used is the agent described herein. In yet another embodiment, the animal is the animal described herein. In 5 another embodiment, the instructions indicate the use of the agent for the treatment or prevention of a cancer described herein.
In still another aspect, the present invention provides a method of inhibiting proliferation of a cancerous cell in an animal, said method comprising administering to said animal a bacteriocin derived from a lactic acid bacteria. In an embodiment, the bacteriocin used is the bacteriocin described herein. In yet another embodiment, the animal is the animal described herein. In another embodiment, the cancer treated or prevented is the cancer described herein.
In another aspect, the present invention provides a method of inhibiting proliferation of a cancerous cell, said method comprising contacting said cell with a bacteriocin derived from a lactic acid bacteria. In an embodiment, the bacteriocin used is the bacteriocin described herein. In yet another embodiment, the animal is the animal described herein. In another embodiment, the cancer treated or prevented is the cancer described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. Pediococcus acidilactici bacteriocin complete coding sequence (SEQ ID NO: 1, GenBank accession number M83924) Figure 2. Pediocin PA-1 polypeptide sequence (SEQ ID N0: 2, GenBank accession number AAA25559) DETAILED DESCRIPTION OF THE INVENTION
In a first aspect, the invention relates to a method of preventing and/or treating cancer. As used herein the terms "preventing", "prevention", "treating" and "treatment" relate to the retardation or inhibition of the onset of a cancer and/or progression of a cancer (e. g.
formation and growth of a primary tumor, dissemination of metastases, growth of metastases, involvement of lymph nodes etc.). The invention also relates to the inhibition of proliferation of cancerous cells. The term "cancer" as used herein relates to the malignant growth of cells. The cancer may be restricted to one organ, tissue or cell type or may be disseminated throughout the body and affect several organs, tissues or cell types. In an embodiment, the cancer may affect bones (e. g. sarcoma, osteosarcoma, rhabdomyosarcoma), brain or spinal cord (e. g. oligodendroglioma, ependymoma, meningioma, lymphoma, schwannoma, medulloblastoma), breasts (e.g. carcinoma in situ such as lobular carcinoma in situ and ductal carcinoma in situ, stage I, II, II and IV carcinoma), endocrine system (e. g. adrenal cancer or pheochromocytoma, pancreatic cancer, parathyroid cancer, pituitary tumors, thyroid cancer), gastrointestinal system (e. g. carcinoma, adenocarcinoma, anal cancer, colon cancer, rectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, hemangiosarcoma and hepatoblastoma, pancreatic cancer, cancer of the small intestine), reproductive system (e. g. cervical cancer, endometrial cancer, uterine cancer, fallopian tube cancer, gestational trophoblastic disease and choriocarcinoma, ovarian cancer, vaginal cancer, vulvar cancer), head and neck (e. g. laryngeal cancer, oropharyngeal cancers, parathyroid cancer, t=hyroid cancer), immune system (e.g acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia, myeloproliferative disorders), lungs (e. g. mesothelioma, non-small cell lung cancer, small-cell lung cancer), lymph nodes (e. g. AIDS-related lymphoma, cutaneous T-cell lymphoma/mucosis fungoides, Hodgkin's disease, non-Hodgkin's disease), and plasma (e. g. multiple myeloma).
According to another aspect, the invention also provides a method of preventing or treating cancer in an animal. In an embodiment, the animal is a mammal, and, in a further embodiment the mammal is a human. In another embodiment, the methods described herein can be used to treat other animals or other mammals (such as a cat, a dog or a horse).
According to yet another aspect, the methods described herein comprise administering an agent to said animal. In an embodiment, the agent is cytotoxic to cancerous cells. As used herein, the term "cytotoxic"
relates to the ability of the agent to halt or retard the growth of cancerous cells or to induce the death of such cells. In another embodiment, the agent may be administered through a route selected from the group consisting of intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal, intratumoral and topical. In an embodiment, the agent may be administered alone or in combination with other chemotherapeutic agents. In another embodiment, the agent may be administered in conjunction (before, simultaneously or after) with a radiation therapy.
The invention also provides a method of treating or preventing cancer, the method comprising administering an agent selected from the group~consisting of (a) a bacteriocin derived from a lactic acid bacteria and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier. As used herein the term "bacteriocin" relates to a polypeptide produced by a microbial cell (e.g. a bacteria), wherein such polypeptide possesses microbicidal (e. g. bacteriocidal) activity. The microbicidal (e. g.
bactericiodal) activity of a bacteriocin can be measured using several techniques known by those skilled in the art, such as the agar spot test (see Example 4). The presence of a bacteriocin can also be assessed with other standard methods such as Western blotting, 2D electrophoresis, capillary electrophoresis, imaging techniques (e. g. specific antibodies coupled to immunof:luorescent compounds or an enzyme that enables colorimet:ric visualisation), ELISA, RIA
and protein micro-array.
In an embodiment, the above-mentioned bacteriocin is derived from a lactic acid bacteria (LAB). Such bacteriocins include, but are not limited to, bavaricin, helveticin, acidocin, lactocin, lactacin, lacticin, nisin, leucocin, lactococcin, pediocin, curvaticin, curvacin, mutacin, mesentericin, plantaricin, streptin and sakacin.
In an embodiment, the bacteriocin is pediocin and, in a further embodiment, the bacteriocin is pediocin PA-1.
Pediocin AcH and pediocin PA-1 are used herein interchangeably. In yet another embodiment, pediocin PA-1 has a sequence substantially identical to the sequence set forth in Figure 2 (e.g. SEQ ID NO: 2) or is encoded by a nucleotide sequence capable of encoding a polypeptide substantially identical to the sequence set forth in Figure 2 (e. g. SEQ ID NO: 1). In another embodiment, amino acid variants of pediocin (such as those described in Johnsen et al., 2000 and Miller et al., 1998) can also be used in the methods described herein. In another embodiment, the bacteriocins and variants described herein may also retain microbicidal (e.g. bacteriocidal) activity. In an embodiment, the pediocin having a variation in its amino acid sequence with respect to the natural pediocin sequence may have enhanced stability, enhanced microbicidal activity and/or enhanced anti-cancer activity.
Agents of the invention can be prepared, for example, by replacing, deleting, or inserting an amino acid residue of a bacteriocin derived from a lactic acid bacteria, with other conservative amino acid residues, i.e., residues having similar physical, biological, or chemical properties, and screening for biological function. It is well known in the art that some modifications and changes can be made in the structure of a polypeptide without substantially altering the biological function of that peptide, to obtain a biologically equivalent polypeptide. The peptides, ligands and domains of the present invention also extend to biologically equivalent peptides, ligands and domains that differ from a portion of the sequence of novel ligands of the present invention by conservative amino acid substitutions.
As used herein, the term "conserved amino acid substitutions"
refers to the substitution of one amino acid for another at a given location in the peptide, where the substitution can be made without substantial loss of the relevant function. In making such changes, substitutions of like amino acid residues can be made on the basis of relative similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like, and such substitutions may be assayed for their effect on the function of the peptide by routine testing. In some embodiments, conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydrophilicity value (e. g., within a value of plus or minus 2.0), where the following may be an amino acid having a hydropathic index of about -1.6 such as Tyr (-1.3) or Pro (-1.6)s are assigned to amino acid residues (as detailed in United States Patent No. 4,554,101, incorporated herein by reference): Arg (+3.0); Lys (+3.0); Asp (+3.0); Glu (+3.0);
5 Ser (+0.3); Asn (+0.2); Gln (+0.2); Gly (0); Pro (-0.5); Thr (-0.4); Ala (-0.5); His (-0.5); Cys (-1.0); Met (-1.3); Val (-1.5); Leu (-1.8); Ile (-1.8); Tyr (-2.3); Phe (-2.5); and Trp (-3.4).
In alternative embodiments, conserved amino acid 10 substitutions may be made where an amino acid residue is substituted for another having a similar hydropathic index (e. g., within a value of plus or minus 2.0). In such embodiments, each amino acid residue may be assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics, as follows: Ile (+4.5); Val (+4.2);
Leu (+3.8); Phe (+2.8); Cys (+2.5); Met (+1.9); Ala (+1.8);
Gly (-0.4); Thr (-0.7); Ser (-0.8); Trp (-0.9); Tyr (-1.3);
Pro (-1.6); His (-3.2); Glu (-3.5); Gln (-3.5); Asp (-3.5);
Asn (-3.5); Lys (-3.9); and Arg (-4.5).
In alternative embodiments, conserved amino acid substitutions may be made where an amino acid residue is substituted for another in the same class, where the amino acids are divided into non-polar, acidic, basic and neutral classes, as follows: non-polar: Ala, Val, Leu, Ile, Phe, Trp, Pro, Met; acidic: Asp, Glu; basic: Lys, Arg, His; neutral:
Gly, Ser, Thr, Cys, Asn, Gln, Tyr.
Conservative amino acid changes can include the substitution of an L-amino acid by the corresponding D-amino acid, by a conservative D-amino acid, or by a naturally-occurring, non-genetically encoded form of amino acid, as well as a conservative substit=ution of an L-amino acid.
Naturally-occurring non-genetically encoded amino acids include beta-alanine, 3-amino-propionic acid, 2,3-diamino propionic acid, alpha-aminoisobutyric acid, 4-amino-butyric acid, N-methylglycine (sarcosine), hydroxyproline, ornithine, citrulline, t-butylalanine, t-butylglycine, N-methylisoleucine, phenylglycine, cyclohexylalanine, norleucine, norvaline, 2-napthylalanine, pyridylalanine, 3-benzothienyl alanine, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, penicillamine, 1,2,3,4-tetrahydro-isoquinoline-3-carboxylix acid, beta-2-thienylalanine, methionine sulfoxide, homoarginine, N-acetyl lysine, 2-amino butyric acid, 2-amino butyric acid, 2,4,-diamino butyric acid, p-aminophenylalanine, N-methylvaline, homocysteine, homoserine, cysteic acid, epsilon-amino hexanoic acid, delta-amino valeric acid, or 2,3-diaminobutyric acid.
In alternative embodiments, conservative amino acid changes include changes based on considerations of hydrophilicity or hydrophobic.ity, size or volume, or charge.
Amino acids can be generally characterized as hydrophobic or hydrophilic, depending primarily on the properties of the amino acid side chain. A hydrophobic amino acid exhibits a hydrophobicity of greater than zero, and a hydrophilic amino acid exhibits a hydrophilicity of less than zero, based on the normalized consensus hydrophobicity scale of Eisenberg et al. (J. Mol. Bio. 179:125-142, 1984). Genetically encoded hydrophobic amino acids include Gly, Ala, Phe, Val, Leu, Ile, Pro, Met and Trp, and genetically encoded hydrophilic amino acids include Thr, His, Glu, Gln, Asp, Arg, Ser, and Lys.
Non-genetically encoded hydrophobic amino acids include t-butylalanine, while non-genetically encoded hydrophilic amino acids include citrulline and homocysteine.
Hydrophobic or hydrc>philic amino acids can be further subdivided based on the characteristics of their side chains. For example, an aromatic amino acid is a hydrophobic amino acid with a side chain containing at least one aromatic or heteroaromatic ring, which may contain one or more substituents such as -OH, -SH, -CN, -F, -Cl, -Br, -I, -N02, -N0, -NH2, -NHR, -NRR, -C (0) R, -C (O) OH, -C (0) OR, -C (0) NH2, -C(0)NHR, -C(0)NRR, etc., where R is independently (Cl-C6) alkyl, substituted (Cl-C6) alkyl, (C1-C6) alkenyl, substituted (C1-C6) alkenyl, (Cl-C6) alkynyl, substituted (Cl-C6) alkynyl, (C5-C20) aryl, substituted (C5-C20) aryl, (C6-C26) alkaryl, substituted (C6-C26) alkaryl, 5-20 membered heteroaryl, substituted 5-20 membered heteroaryl, 6-26 membered alkheteroaryl or substituted 6-26 membered alkheteroaryl. Genetically encoded aromatic amino acids include Phe, Tyr, and Tryp, while non-genetically encoded aromatic amino acids include phenylglycine, 2-napthylalanine, beta-2-thienylalanine, 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, 4-chlorophenylalanine, 2-fluorophenylalanine3-fluorophenylalanine, and 4-fluorophenylalanine.
An apolar amino acid is a hydrophobic amino acid with a side chain that is uncharged at physiological pH and which has bonds in which a pair of electrons shared in common by two atoms is generally held equally by each of the two atoms (i.e., the side chain is not polar). Genetically encoded apolar amino acids include Gly, Leu, Val, Ile, Ala, and Met, while non-genetically encoded apolar amino acids include cyclohexylalanine. Apolar amino acids can be further subdivided to include aliphatic amino acids, which is a hydrophobic amino acid having an aliphatic hydrocarbon side chain. Genetically encoded aliphatic amino acids include Ala, Leu, Val, and Ile, while non-genetically encoded aliphatic amino acids include norleucine.
A polar amino acid is a hydrophilic amino acid with a side chain that is uncharged at physiological pH, but which has one bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms.
Genetically encoded polar amino acids include Ser, Thr, Asn, and Gln, while non-genetically encoded polar amino acids include citrulline, N-acetyl lysine, and methionine sulfoxide.
An acidic amino acid is a hydrophilic amino acid with a side chain pKa value of. less than 7. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Genetically encoded acidic amino acids include Asp and Glu. A basic amino acid is a hydrophilic amino acid with a side chain pKa value of greater than 7. Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion. Genetically encoded basic amino acids include Arg, Lys, and His, while non-genetically encoded basic amino acids include the non-cyclic amino acids ornithine, 2,3,-diaminopropionic acid, 2,4-diaminobutyric acid, and homoarginine.
The above classifications are not absolute and an amino acid may be classified in more than one category. In addition, amino acids can be r_lassified based on known behaviour and or characteristic chemical, physical, or biological properties based on specified assays or as compared with previously identified amino acids. Amino acids can also include bifunctional moieties having amino acid-like side chains.
Conservative changes can also .include the substitution of a chemically derivatised moiety for a non-derivatised residue, by for example, reaction of a functional side group of an amino acid. Thus, these substitutions can include compounds whose free amino groups have been derivatised to amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Similarly, free carboxyl groups can be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides, and side chains can be derivatized to form 0-acyl or 0-alkyl derivatives for free hydroxyl groups or N-im-benzylhistidine for the imidazole nitrogen of histidine. Peptide analogues also include amino acids that have been chemically altered, for example, by methylation, by amidation of the C-terminal amino acid by an alkylamine such as ethylamine, ethanolamine, or ethylene diamine, or acylation or methylation of an amino acid side chain (such as acylation of the epsilon amino group of lysine). Peptide analogues can also include replacement of the amide linkage in the peptide with a substituted amide (for example, groups of the formula -C(O)-NR, where R is (C1-C6) alkyl, (C1-C6) alkenyl, (C1-C6) alkynyl, substituted (C1-C6) alkyl, substituted (C1-C6) alkenyl, or substituted (C1-C6) alkynyl) or isostere of an amide linkage (for example, -CH2NH-, -CH2S, -CH2CH2-, -CH=CH- (cis and trans), -C(O)CH2-, -CH(OH)CH2-, or -CH2S0-).
"Homology" and "homologous" refers to sequence similarity between two peptides or two nucleic acid molecules. Homology can be determined by comparing each position in the aligned sequences. A degree of homology between nucleic acid or between amino acid sequences is a function of the number of identical or matching nucleotides or amino acids at positions shared by the sequences. As the term is used herein, a nucleic acid sequence is "homologous"
to another sequence if the two sequences are substantially identical and the functional activity of the sequences is conserved (as used herein, the term "homologous" does not infer evolutionary relatedness). Two nucleic acid sequences are considered substantially identical if, when optimally aligned (with gaps permitted), they share at least about 50%
sequence similarity or identity, or if the sequences share defined functional motifs. In alternative embodiments, sequence similarity in optimally aligned substantially 5 identical sequences may be at least 600, 70%, 750, 800, 850, 900 or 950. As used herein, a given percentage of homology between sequences denotes the degree of sequence identity in optimally aligned sequences. An "unrelated" or "non-homologous" sequence shares less than 40% identity, though 10 preferably less than about 25 o identity, with any of SEQ ID
NOs. 1 and 2.
Substantially complementary nucleic acids are nucleic acids in which the complement of one molecule is substantially identical to the other molecule. Two nucleic 15 acid or protein sequences are considered substantially identical if, when optimally aligned, they share at least about 70o sequence identity. In alternative embodiments, sequence identity may for example be at least 750, at least 800, at least 850, at least 900, or at least 95%. Optimal alignment of sequences for comparisons of identity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith arid Waterman, 1981, Adv. Appl.
Math 2: 482, the homology alignment algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48:443, the search for similarity method of Pearson and Lipman, 1988, Proc. Natl.
Acad. Sci. USA 85: 2444, and the computerised implementations of these algorithms (such as CAP, BESTFIT, FASTA and TFASTA
in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, WI, U.S.A.). Sequence identity may also be determined using the BLAST algorithm, described in Altschul et al., 1990, J. Mol. Biol. 21.5:403-10 (using the published default settings). Software for performing BLAST analysis may be available through the National Center for Biotechnology Information (through the Internet at http://www.ncbi.nlm.nih.gov/). The BLAST algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold. Initial neighbourhood word hits act as seeds for initiating searches to find longer HSPs. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased.
Extension of the word hits in each direction is halted when the following parameters are met: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program may use as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (Henikoff and Henikoff, 1992, Proc. Natl. Acad. Sci.
USA 89: 10915-10919) alignments (B) of 50, expectation (B) of 10 (or 1 or 0.1 or 0.01 or 0.()01 or 0.0001), M=5, N=4, and a comparison of both strands. One measure of the statistical similarity between two sequences using the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. In alternative embodiments of the invention, nucleotide or amino acid sequences are considered substantially identical if the smallest sum probability in a comparison of the test sequences is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
An alternative indication that two nucleic acid sequences are substantially complementary is that the two sequences hybridize to each other under moderately stringent, or preferably stringent, conditions. Hybridisation to filter-bound sequences under moderately stringent conditions may, for example, be performed in 0.5 M NaHP04, 7o sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.2 x SSC/O.lo SDS at 42°C (see Ausubel, et al. (eds), 1989, Current Protocols in Molecular Biology, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3). Alternatively, hybridization to filter-bound sequences under stringent conditions may, for example, be performed in 0.5 M NaHP04, 7o SDS, 1 mM EDTA at 65°C, and washing in 0.1 x SSC/O.lo SDS at 68°C (see Ausubel, et al.
(eds), 1989, supra). Hybridization conditions may be modified in accordance with known methods depending on the sequence of interest (see Tijssen, 1993, Laboratory Techniques in Biochemistry and Molecular Biology -- Hybridization with Nucleic Acid Probes, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York). Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point for the specific sequence at a defined ionic strength and pH.
In another aspect, t=he invention provided methods of using a bacteriocin derived from a lactic acid bacteria (e.g. in the form of a composition or not) to treat or prevent cancer. As used herein, the term "lactic acid bacteria" (LAB) is a class of bacteria that are capable of producing lactic acid. Usually, LAB are gram positive bacteria. In embodiments, some LAB can be used in the preparation (e. g. fermentation) of various food products (such as milk, meat, vegetable and fruit). In embodiments, the lactic acid bacteria species include, but are not limited to Streptococcus spp., Lactococcus spp., Lactobacillus spp., Pediococcus spp., Bifidobacterium spp., Leuconostoc spp, and Enterococcus spp. In an embodiment, the bacteriocin is derived from Pediococcus acidilactici and, in a further embodiment, the bacteriocin is derived from from Pediococcus acidilactici PAC 1Ø
As used herein the term "derived from a LAB" is defined as either produced by a LAB or being of LAB origin but produced by other means (e. g. expressed in another system; e.g. a prokaryotic system, such as E. coli).
In yet another embodiment, the bacteriocin described herein is substantially pure. A compound or agent that is "substantially pure" is separated from the components that naturally accompany it. Typically, a compound is substantially pure when it is at least 600, more generally 750 or over 900, by weight, of the total material in a sample. Thus, for example, a polypeptide that is chemically synthesised or produced by recombinant technology will generally be substantially free from its naturally associated components. A nucleic acid molecule is substantially pure when it is not immediately contiguous with (i.e. covalently linked to) the coding sequences with which it is normally contiguous in the naturally occurring genome of the organism from which the DNA of the invention is derived. A
substantially pure compound can be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid molecule encoding a polypeptide compound; or by chemical synthesis. Purity can be measured using any appropriate method such as column chromatography, gel electrophoresis, HPLC, etc.
In a further embodiment, the agent described herein is substantially free of bacterial contaminants from the lactic acid bacteria (e.g. Pediococcus spp.) from which it is derived. Such contaminants may be cell wall components, organelles (such as the Golgi, endoplasmic reticulum, ribosomes), nuclear components (such as the nuclear wall, the nucleus or the nucleic acid it contains), nucleotides (such as ribonucleotides and/or deoxyribonucleotides), lipids, proteins and protein fragments, etc. In another embodiment, the bacteriocin is isolated/purified from the lactic acid bacteria in which it is produced (refer to the methods described above and in the examples).
The invention also relates to a method of treating or preventing cancer, said method comprising administering a bacteriocin derived from a lactic acid bacteria and/or a composition comprising such a bacteriocin and a suitable carrier. In an embodiment, the bacteriocins (e. g. pediocin) described herein may be modified/adapted to be more resistant (e. g. less degraded) in the presence of gastro-intestinal juices. In an embodiment, the agent may be administered in a way such that the bacteriocin does not come into contact with the gastro-instestinal (GI) tract (e. g. intravenous administration). In another embodiment, the amino acid sequence of the bacteriocin can be modified to increase its stability in the GI tract. Such modifications include, but are not limited to, replacing o-amino acids by z-amino acids.
In yet another embodiment, the agent can be coated with or formulated with a material that enables the rapid and specific delivery of the agent to a specific location in the GI tract, thereby limiting the contact between the bacteriocin and the GI juices. In another embodiment, the bacteriocin can be provided in the form of a food product or a nutraceutical comprising the bacteriocin, such as a fermented food product or a fermented milk. The incorporation of bacteriocins into a food product or nutraceutical may prevent the degradation of the bacteriocins.
5 In various embodiments, the agent described herein, may be used therapeutically in formulations or medicaments to prevent or treat cancer. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of an agent is administered in a pharmacologically acceptable 10 formulation or nutraceutically acceptable formulation, e.g.
to a patient or subject in need thereof. Accordingly, the invention also provides therapeutic compositions comprising a bacteriocin derived from a lactic acid bacteria and a carrier. In an embodiment, the carrier is a pharmaceutically 15 acceptable carrier or a nutraceutically acceptable carrier.
As used herein, the ~~nutraceutically acceptable carrier" is defined as a carrier that is suitable for administration in a nutraceutical. For those skilled in the art, a nutraceutical is defined as any substance that is a food or a part of a 20 food and provides medical or health benefits, including the prevention and treatment of disease. Such products may range from isolated nutrients, dietary supplements and specific diets to genetically engineered designer foods, herbal products, and processed foods such as cereals, soups and beverages. This definition also includes a bio-engineered designer vegetable food, rich in antioxidant ingredients, and a functional food or pharmafood. A nutraceutical is also defined as a product isolated or purified from foods, and generally sold in medicinal forms not usually associated with food and demonstrated to have a physiological benefit or provide protection against or improvement of a disease condition. In an embodiment, the nutraceutically acceptable carrier may be a food product (e. g. soy derivative, milk derivative, meat product, juice, etc.) and, in a further embodiment, it may be a fermented food product. Fermented food products include, but are not limited to, fermented milk products.
In one embodiment, such compositions include a bacteriocin derived from a lactic acid bacteria in a therapeutically or prophylactically effective amount sufficient to treat or prevent cancer in an animal. The composition may be soluble in an aqueous solution at a physiologically acceptable pH.
A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as the prevention or treatment of a cancer (e.g. inhibition or reduction of growth of a primary tumor, inhibition or reduction of implantation or growth of metastases, inhibition or reduction of lymph nodes involvement). A therapeutically effective amount of a bacteriocin derived from a lactic acid bacteria may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the agent to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount"
refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as preventing or inhibiting the rate of cancer onset or progression. A prophylactical:ly effective amount can be determined as described above for the therapeutically effective amount. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions.
As used herein ~~pharmaceutically acceptable carrier" or ~~excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration.
Alternatively, the carrier can be suitable for intravenous, intraperitoneal, intramuscular, sublingual, intratumoral or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage.
The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the :like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, a bacteriocin derived from a lactic acid bacteria can be administered in a time release formulation, for example in a composition which includes a slow release polymer. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems.
Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.
Sterile injectable solutions can be prepared by incorporating the active compound (e. g. a bacteriocin derived from a lactic acid bacteria) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. In accordance with an alternative aspect of the invention, a bacteriocin derived from a lactic acid bacteria may be formulated with one or more additional compounds that enhance the solubility of the bacteriocin.
In accordance with another aspect of the invention, therapeutic compositions of the present invention, comprising an agent (e. g. a bacteriocin derived from a lactic acid bacteria and/or a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier), may be provided in containers or packages (e. g. commercial packages) which further comprise instructions for use of the agent for preventing and/or treating of cancer.
Accordingly, the invention further provides a package (e. g. commercial package) comprising a bacteriocin derived from a lactic acid bacteria or the above-mentioned composition together with instructions for the use of the bacteriocin and/or composition for the prevention and/or treatment of cancer.
The invention further provides use of a bacteriocin derived from a lactic acid bacteria or the above-mentioned composition for the prevention and/or treatment of cancer.
The invention further provides the use of a bacteriocin derived from a lactic acid bacteria for the preparation of a medicament for prevention and/or treatment of cancer.
In yet another aspect, the invention also provides a gene therapy method for treating or preventing cancer.
Nucleic acids encoding a bacteriocin derived from a lactic acid bacteria may be delivered to cells in vivo using methods such as direct injection of DNA, receptor-mediated DNA
uptake, viral-mediated transfection or non-viral transfection and lipid based transfection, all of which may involve the use of gene therapy vectors. Direct injection has been used to introduce naked DNA into cells in vivo (see e.g., Acsadi et al. (1991) Nature 332:815-818; Wolff et al. (1990) Science 247:1465-1468). A delivery apparatus (e.g., a Eugene gun") for injecting DNA into cells in vivo may be used. Such an apparatus may be commercially available (e. g., from BioRad).
Naked DNA may also be introduced into cells by complexing the 5 DNA to a can on, such as polylysine, which is coupled to a ligand for a cell-surface receptor (see for example Wu, G.
and Wu, C. H. (1988) J. Biol. Chem. 263:14621; Wilson e1. al.
(1992) J. Biol. Chem. 267:963-967; and U.S. Pat. No.
5,166,320). Binding of the DNA-ligand complex to the 10 receptor may facilitate uptake of the DNA by receptor-mediated endocytosis. A DNA-ligand complex linked to adenovirus capsids which disrupt endosomes, thereby releasing material into the cytoplasm, may be used to avoid degradation of the complex by intracellular lysosomes (see for example 15 Curiel e1 al. (1991) Proc. Natl. Acad. Sci. USA 88:8850;
Cristiano et al. (1993) Proc. Natl. Acad. Sci. USA 90:2122-2126) .
Defective retroviruses are well characterized for use as gene therapy vectors (for a review see Miller, A. D.
20 (1990) Blood 76:271). Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard 25 laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines include .psi.Crip, .psi.Cre, .psi.2 and .psi.Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464; Wilson et al. (1988) Proc. Natl. Acad. Sci. USA 85:3014-3018; Armentano et al.
(1990) Proc. Natl. Acad. Sci. USA 87:6141-6145; Huber et al.
(1991) Proc. Natl. Acad. Sci. USA 88:8039-8043; Ferry et al.
(1991) Proc. Natl. Acad. Sci. USA 88:8377-8381; Chowdhury et al. (1991) Science 254:1802-1805; van Beusechem et al. (1992) Proc. Natl. Acad. Sci. USA 89:7640-7644; Kay et al. (1992) Human Gene Therapy 3:641-647; Dai et al. (1992) Proc. Natl.
Acad. Sci. USA 89:10892-10895; Hwu et al. (1993) J. Immunol.
150:4104-4115; U.S. Pat. No. 4,868,116; U.S. Pat. No.
4,980,286; PCT Application WO 89/07136; PCT Application WO
89/02468; PCT Application WO 89/05345; and PCT Application WO
92/07573).
Adeno-associated virus (AAV) may be used as a gene therapy vector for delivery of DNA for gene therapy purposes.
AAV is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al. Curr. Topics in Micro. and Immunol.
(1992) 158:97-129). AAV may be used to integrate DNA into non-dividing cells (see for example Flotte et al. (1992) Am.
J. Respir. Cell. Mol. Biol. 7:349-356; Samulski et al. (1989) J. Virol. 63:3822-3828; and McLaughlin et al. (1989) J.
Virol. 62:1963-1973). An AAV vector such as that described in Tratschin et al. (1985) Mol. Cell. Biol. 5:3251-3260 may be used to introduce DNA into cells (see for example Hermonat et al. (1984) Proc. Natl. Acad. Sci. USA 81:6466-6470; Tratschin et al. (1985) Mol. Cell. Biol. 4:2072-2081; Wondisford et al.
(1988) Mol. Endocrinol. 2:32-39; Tratschin et al. (1984) J.
Virol. 51:611-619; and Flotte et al. (1993) J. Biol. Chem.
268:3781-3790). Lentiviral gene therapy vectors may also be adapted for use in the invention.
General methods for gene therapy are known in the art. See for example, U.S. Pat. No. 5,399,346 by Anderson et al. A biocompatible capsule for delivering genetic material is described in PCT Publication WO 95/05452 by Baetge et al.
Methods of gene transfer into hematopoietic cells have also previously been reported (see Clapp, D. W., et al., Blood 78:
1132-1139 (1991) Anderson, Science 288:627-9 (2000): and, Cavazzana-Calvo et al., Science 288:669-72 (2000)).
In another embodiment, a vector encoding a bacteriocin derived from a lactic acid bacteria can be introduced into a cell in vitro. Such cell may, in an embodiment, produce and/or secrete the bacteriocin. This genetically modified cell can then be inserted into a host having a cancer. In an embodiment, the genetically modified cell is inserted into the host in proximity to the tumor or the metastases. In yet another embodiment, the inserted genetically modified cell produces or secretes the bacteriocin into the host. In another embodiment, the genetically modified cell is autologous or non-autologous to the host.
Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. In the claims, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to". The following examples are illustrative of various aspects of the invention, and do not limit the broad aspects of the invention as disclosed herein.
EXAMPII~ES
Antimicrobial peptides, such as bacteriocins, possess cationic and amphipathic properties which allow interactions with the membrane of living cells. Many such cationic peptides could have interesting and various biomedical and health applications (Marshall and Arenas, 2003). Potential uses may be as components of cosmetics (Reisch, 2002), as antibiotics (Hancock and Lehrer, 1998), as analgesics (Crescenzi et al., 2000), and as agents to prevent oral mucositis (Chen et al., 2000) or to fight herpes viruses (Wachsman et al., 1999; Wachsman et al., 2003). Some bacteriocins have been reported to also possess antitumor activity (Winder et al., 1998).
Bacteriocins produced by lactic acid bacteria (LAB) are antimicrobial peptides, and they have recently gained interest for their potential as food preservatives, as well as for medical applications (Nes and Holo, 2000). An example is nisin, which is produced by Lactococcus lactis. This natural inhibitor is well known (Ross et al., 1999) and has been used for a long time as a food preservative (Breukink and Kruijff, 1999). Most recently, it has been considered to be useful for the treatment of gastric Helicobacter and/or ulcerous infections (Guder et al., 2000; Hancock, 1997; Ross et al., 1999; Uteng et al., 2002). Other LAB bacteriocins, belonging to the class IIa (pediocin, lactacine, etc.), are very interesting and they are starting to be considered seriously as a group of antimicrobial compounds worth investigating for future medical use (Nes and Holo, 2000).
Pediocin PA-l, one of the known class IIa bacteriocins, is produced by Pediococcus acidilactici PAC 1.0 and is strongly active against Listeria monocytogenes (Bhunia et al., 1988). The primary structure of pediocin PA-1 consists of 44 amino acids and its theoretical molecular weight is 4624 Da (refer to figure 2, SEQ ID NO: 2), in the presence of its two disulfide bonds, known to be very important for its biological activity (Gaussier, 2003; Henderson et al., 1992;
Rodriguez et al., 2002). Advances in the understanding of pediocin PA-1 structure, mode of action and biosynthesis will greatly increase the potential usefulness of pediocin PA-1 in different fields. Recent studies revealed that production of recombinant pediocin PA-1 in the methylotrophic yeast Pichia pastoris led to unexpected inhibition of its biological activity (Example 2). This astonishing phenomenon raised several questions and, especially, it has demonstrated a particular feature of the function and/or structure of pediocin PA-l, i.e., that pediocin PA-1 may possess a somewhat "collagen-like" nature.
Recently, the role of collagen-derived proteolytic fragments in angiogenesis was investigated (Marneros and Olsen, 2001). Antitumoral effects have been demonstrated for cecropin, melittin and magainine (Baker et al., 1993; Jaynes et al., 1989; Moore et al., 1994; Ohsaki et al., 1992;
Sharma, 1992). In the case of melittin, the hyperactivation of phospholipase A2 in ras-transformed cells was in part responsible for the antitumoral activity (Winder et al., 1998).
In the studies described herein, the potential of growth inhibition of pediocin PA-1 on the A-549 human lung carcinoma cell line and the DLD-1 human colon adenocarcinoma cell line was evaluated.
Example I - Production of native/natural pediocin PA-I
Pediococcus acidilactici strain PAC 1.0 (Quest International, Sarasota, Fla.) was cultivated in a 20 L
fermentor (Chemap, Switzerland) equipped with pH and p02 electrodes (Ingold), a foam sensor, and a mechanical foam breaker. It was grown in 16 L of Lactobacilli MRS broth (Oxoid); a 1% (v/v) inoculum was used and incubation was done at 37°C for 18 h at an agitation rate of 200 rpm. No 5 additional aeration was provided and no chemical antifoam was added during cultivation.
The cells were separated from the broth by centrifugation (50008, 15 min, 20°C). The supernatant fluid was concentrated 13-fold using a 0.5m2 1 kDa (cut-off) 10 regenerated cellulose membrane k(PCACTM membrane, Millipore), then, diafiltered against 5mM ammonium acetate buffer, pH°5.0, using a PelliconTM system (Millipore) with a Masterflex peristaltic pump at a recirculation rate of 200 ml/min. The process was performed at room temperature.
15 Ion exchange chromatography (IEX). Pediocin PA-1 purification was achieved using a modification of the procedure described by Gaussier et al. (2002). Pediocin PA-1 from the concentrated supernatant fluid (1200 ml) was captured using a SP-Sepharose Fast FlowTM can on exchange 20 column (Amersham). The C26/40 column was packed with 80 ml of resin and connected to a FPLC chromatography system coupled to an UVl-detector (Amersham; reading at OD280 nm). The column was equilibrated with 10 CV (CV = column volume) of 5mM ammonium acetate buffer, pH 5.0 (Buffer A). The pediocin 25 PA-1 solution was applied to the column at a rate of 226 cm/h, then, the column was washed successively with Buffer A and Buffer A containing 0.25M NaCl. Pediocin PA-1 was eluted from the column with Buffer A containing 0.5M
NaCl.
30 Hydrophobic interaction chromatography (HIC) Screening of chromatography media. Several HIC media with varying hydrophobicity were tested, namely: Butyl-SepharoseTM, Amersham; Butyl-650M, Tosohaas; Octyl-SepharoseTM CL 4B, Amersham; Phenyl-SepharoseTM, Amersham; Phenyl-650M, Tosohaas.
Media (1 ml) were equilibrated with 5mM ammonium acetate buffer, pH 5.0 (Buffer A) containing 0.5M NaCl, mixed with 5 ml of the SP-SepharoseTM FF eluate (previous step) and the mixtures were incubated for 1 h at room temperature. A first wash with Buffer A containing 0.5M NaCl was performed followed by elution with Buffer A (5mM ammonium acetate buffer, pH 5.0) and then, by a second elution with Buffer A
containing 500 (v/v) acetonitrile. Biorad Econo-ColumnsTM were used for the screening work and elution was performed by gravity. Eluate fractions were analyzed for pediocin PA-1's biological activity by an agar spot test on a MRS agar medium (Rodriguez et al, 2002).
Refinement of the HIC method. The active fractions collected from the SP-SepharoseTM column were pooled and applied to an Octyl Sepharose~~~M CL-4B hydrophobic interaction column (HR5/5, 1 ml CV, Amer~;ham) using the FPLC system. The column was equilibrated with Buffer A containing 0.5M NaCl.
The pediocin solution was applied to the HIC column at the rate of 306 cm/h, the column was washed with the same equilibration buffer, followed by a second wash with Buffer A. Pediocin PA-1 was eluted with Buffer A containing 500 (v/v) acetonitrile. All of the initial developmental work was performed using 1 ml CV HR5/5 HIC columns (Amersham). Later, a 40 ml CV XK26 column (Amersham) was used to generate more pediocin PA-1 material. The active fractions were pooled and concentrated (13-fold) using a 350 ml Stir Cell system (Amicon) and a lkDa (cut-off) regenerated cellulose membrane (YMl, DiafloTM ultrafiltration membrane, Amicon) ending with diafiltration against water (HPLC grade). The retentate was lyophilized (Flexi-dryTM, FTS Systems Inc.) and the material was stored at 4°C under a NZ atmosphere.
Example 2 - Production of recombinant pediocin PA-I in Pichia pastoris Strains, plasmids and culture conditions.
Escherichia coli TOP10 was grown in Luria-Bertani (LB) broth (lo tryptone, 1o NaCl, 0.50 yeast extract, pH 7.0). E.coli transformants were grown in L,ow Salt Luria-Bertani (LSLB) medium, supplemented with zeocin (25~g/ml) overnight at 37°C.
Pediococcus acidilactici PAC1.0 and Pediococcus pentosaceus FBB63 were grown in Lactobacilli MRS broth (Oxoid) for 18h at 37°C. Yeast strains were cultured in YPD (lo yeast extract, 2% peptone, 2o glucose) medium, whereas yeast transformants were grown in baffled shake flasks under selective conditions in buffered glycerol-complex medium (BMGY: to yeast extract, 2o peptone, 100mM potassium phosphate, pH 6.0, 1.340 yeast nitrogen base without amino acids, 4X10-So biotin, to glycerol) until cultures reached an OD6oonm between 2 and 6.
The cultures were harvested by centrifugation (5000 g, 15 min, 4°C) and the cells were grown for another 3 days at 30°C in buffered methanol complex medium (BMMY: to yeast extract, 2% peptone, 100mM potassium phosphate, pH 6.0, 1.340 yeast nitrogen base without amino acids, 4X10-50 biotin, to methanol) for the induction of pediocin PA-1 gene expression.
Samples were taken at different times (0, 6, 12, 24, 48, 72°h) for analysis. Experiments were performed according to the guidelines supplied by the EasySelectTM Pichia Expression Kit (Invitrogen Corporation).
Cloning of pedA and plasmid construction. A DNA
fragment encoding the mature domain of pedi.ocin PA-1 was obtained by polymerase chain reaction (PCR) amplification of pSRQl1 DNA isolated from Pediococcus acidilactici PAC1.0 using the QIAprepTM Spin Miniprep Kit protocol (QIAgen) and with an alkaline lysis procedure (2001 of a cold solution containing 50mM glucose, lOmm EDTA, 25mM Tris pH 8.0 and 4 mg/ml of lysozyme, from Sigma, were added after step 3).
The sequence of the 5' primer used for amplification (5'-AAA
AAA CTC GAG AAA AGA GAG GTC GAA GCT AAA TAC TAC GGT AAT GGG-3' [SEQ ID NO: 3]) begins with 6xA nucleotide clamp, followed by a XhoI restriction enzyme site (CTCGAC), the Kex2 signal cleavage sequence (AAAAGAGAGGTCGAAGCT [SEQ ID N0: 4]) and ends with a 18 nucleotide sequence complementary to the first nucleotides of the pedA gene encoding for the mature peptide form. The 3' primer (5'-AAA AAA GTC GAC TTA TCA CTA GCA TTT
ATG ATT ACC TTG ATG TC-3'[SEQ ID NO: 5]) contains 6xA
nucleotide clamp, followed by an AccI restriction enzyme site (GTCGAC), and the stop codons to end with a 23 nucleotide sequence complementary to the final eight codons of the pedA
gene. PCR amplification was performed with 40U of rTaq DNA
polymerase (Amersham) per ml, 1.35 pg of pSRQll template per ml, 1.25mM of each nucleoside triphosphate, and 2 ~g of each primer per ml. PCR was performed to amplify DNA with a hot start at 96°C for 1 min and then 30-cycles of amplification (96°C, 30s for strand denaturation, 55°C, 30s for primer annealing, and 72°C, 60s for primer extension) followed by a final extension at 72°C for 2 min. The PCR product was purified using the QIAquickTM PCR Purification Kit Protocol (QIAgen) and digested with XhoI and AccI restriction endonucleases (Amersham and New England Biolabs, respectively). The resulting fragment was purified by agarose gel electrophoresis using the QIAexTM II agarose gel extraction kit (QIAgen) and ligated with T4 DNA Ligase (New England Biolabs) between the XhoI and AccI restriction sites within the pPICZaA vector. pPICZaA was pre-digested with the same enzymes. Ligation mixtures were transformed into competent E.coli TOP10 cells (TOPO TA Cloning, Version K, Invitrogen). In vitro DNA manipulation (digestion, ligation) for cloning in E. coli were performed as described by Sambrook et al. (1989). The pPICZaA-pedA expression plasmid, isolated using the QIAgen Plasmid Maxi Protocol (QIAgen), was identified by restriction enzyme digestion with XhoI/AccI and BamHI/SacI (New England Biolabs). The pedA gene region was confirmed by double-stranded DNA sequencing with AmpliTaq DNA
polymerase (ABI PRISMTM Dye Terminator Cycle Sequencing Ready Reaction Kit) using an ABI 377XL DNA Sequencer (Applied Biosystems). For PCR sequencing reactions, 5' and 3' AOXl primers were used to confirm that the pedA gene was in frame with the C-terminal of the a-factor (EasySelectTM Pichia Expression Kit, Invitrogen Corporation). PCR reactions were purified on a Centri-SepTM column (Applied Biosystems) prior to performing sequence analysis. pPICZaA (10 fig) and pPICZaA-pedA (10 fig) vectors were linearized with 40U of SacI
restriction endonuclease (Amersham) following the recommendations given by the EasySelectTM Pichia Expression Kit (Invitrogen Corporation). Linearized vectors were electroporated into P. pastoris. Electro-competent cells (80 ~l) were mixed with DNA solution (10 fig) in a 0.2 cm gap cuvette chilled on ice. Electroporation was carried out using a Gene PulserTM (Bio-Rad) with the following parameters:
1.5 kV, 40052, 25 ~F to a final field strength of 7.5 kV cm-1.
After cells had been pulsed, 1 ml of ice-cold sterile 1M
sorbitol was immediately added to the cuvette, the cell suspension was transferred into a test tube, and the mixture incubated at 30°C for 1h30. Transformed clones were selected on Yeast Extract Peptone Dextrose Sorbitol medium (YPDS: 1%
yeast extract, 2o peptone, 2o dextrose, 1M sorbitol, 2% agar) containing zeocin (100 ~g/ml). Transformants were also tested on both Minimal Dextrose Medium, with and without histidine, (1.340 yeast nitrogen base without amino acids, 4X10-5o biotin, 2o dextrose, with and without 0.0040 histidine, 1.50 agar) and Minimal Methanol Medium, with and without histidine, (1.340 yeast nitrogen base without amino acids, 4X10-5o biotin, 2o methanol, with and without 0.004%
5 histidine, 1.50 agar) plates to confirm the Mut+ phenotype of the X-33 and GS115 strains.
Detection of activity of pediocin PA-1 by agar spot test. All transformants were grown in shake flasks as mentioned before and tested by agar spot test on MRS medium 10 (Parrot et al., 1990) for detection of biological activity. A
MRS plate (1.50 (w/v) agar, 20 ml) was covered with 5 ml of soft agar (0.80 (w/v) agar) containing an overnight MRS-grown culture of the indicator strain P. pentosaceus (adjusted to an OD6oonm of 0.1, Beckman DU 640 Spectrophotometer).
15 Supernatant fluid samples were filtered using a 0.22 ~m membrane (Syringe Driven Filter Unit, Millex-HV, 4 mm) and 5 ~l of each sample was added to the surface of the soft agar. The plates were incubated for 18h at 37°C and examined for the presence of clear zones indicating growth inhibition.
20 The recombinant Pichia was grown in baffled shake flasks in BMGY medium until glycerol was exhausted and, then, in BMMY medium with methanol (0.50 (v/v)) for 3 days. The cultures were harvested by centrifugation (5000g, 15 min, 4°C) and the supernatant fluids analyzed. Expression levels 25 were monitored by quantitative ELISA testing. A pediocin concentration of 74 ~g/ml was achieved in Pichia comparison with 6 ~g/ml for the natural producing strain of P.
acidilactici (Example 1). However, biological activity against P. pentosaceus was not detected in the supernatant 30 fluids of the P. pastoris cultures tested several times over a 72 h induction period (0, 6, 12, 24, 48 and 72h).
Example 3 - Materials and Methods - Anticancer activity of natural and recombinant pediocin PA-1 Pediocin PA-1. Both highly purified pediocin PA-1 (Example 1), obtained from the naturally producing Pediococcus acidilactici PAC 1.0 strain (Quest International, Sarasota, Fla.), and semi-purified recombinant pediocin PA-1 (Example 2), produced by Pichia pastoris (KMH71, MutS
phenotype, Invitrogen) were tested in this study. Production and purification was done as described earlier for natural pediocin PA-1 (Example 1) and for the recombinant pediocin PA-1 (Example 2).
Cell culture. The human lung carcinoma cell line A-549 and the human colon adenc>carcinoma cell line DLD-1 were obtained from the American Type Culture Collection (ATCC).
I5 Both cell lines were cultured in minimum essential medium containing Earle's salts and L-glutamine (Mediatech Cellgro, VA), to which were added loo fetal bovine serum (Hyclone), vitamins (1X), penicillin (100 I.U./ml) and streptomycin (100 ~g/ml), essential amino acids (1X) and sodium pyruvate (1X) (Mediatech Cellgro, VA). Cells were kept at 37°C in a humidified environment containing 5o CO2.
Anticancer activity assay. Exponentially growing cells were plated in 96-well microplates (Costar, Corning inc.) at a density of 5 x 103 cells per well in 100 ~l of culture medium and were allowed to adhere for 16 h before treatment. Increasing concentrations of both natural and recombinant pediocin PA-1 in culture medium (minimum essential medium, described previously) were then added (100 ~l per well). The cells were incubated for 48 h in the presence or absence of pediocin PA-1. The cell growth was assessed using the resazurin reduction test (0'Brien et al., 2000). Fluorescence was measured on an automated 96-well Fluoroskan Ascent F1TM plate reader (Labsystems) using excitation and emission wavelengths of 350 nm and 590 nm, respectively. Anticancer activity was expressed as the concentration of natural or recombinant pediocin PA-1 inhibiting cell growth by SOo (ICSO). The experiment was repeated and produced very similar results.
Example 4 - Results - Anticancer activity of natural and recombinant pediocin PA-I
Anticancer drug discovery using human tumor cell lines has attracted increasing interest since the mid-1980s (Baguley and Marshall, 2004). Some antimicrobial peptides are known to exhibit antitumor activity in tumor-derived cell lines (melittin, cecropin, magainin) (Winder et al., 1998).
The potential anticancer activity of pediocion PA-1 was evaluated herein. Both natural pediocin PA-1 and recombinant pediocin PA-l, obtained in an inactive form from the yeast Pichia pastoris, were assayed for their anticancer activity on two carcinoma cell lines using the resazurin reduction test (0'Brien et al., 2000). The two cell lines tested were a human lung carcinoma cell line (A-549) and a human colon adenocarcinoma cell line (DLD-1). Natural, highly purified pediocin PA-1 showed a antiproliferative effect on both cell lines (two separate experiments) while no growth inhibition was observed for recombinant, semi-purified pediocin PA-1 (Table 1 - below). Natural pediocin PA-1 showed very similar ICSO (~M) values for both human cell lines, which were 1.66 ~M
for lung tumoral cells and 1.61 ~M for colon tumoral cells.
Such values are indicative of significant clinical potential and have also been reported for other therapeutic agents of medicinal importance (DNA-reactive compounds, antimetabolites, mitotic poisons, topoisomerase poisons)(Luber and Hardy, 2001).
TABLE 1: Anticancer activity (ICso) of highly purified natural pediocin PA-1*
Human cell line Pediocin PA-1 ICso (~g/ml) A-549a 7.66 ~ 0.69 (1.66 ~ 0.15 uM) DLD-1° 7.43 ~ 0.45 (1.61 ~ 0.10 uM) * Recombinant pediocin PA-1 produced by P. pastoris showed no anticancer activity under the same conditions.
Human lung carcinoma cell line.
Human colon adenocarcinoma cell line.
In the past, some authors have demonstrated that partially purified bacteriocins (PPBs) (Farkas-Himsley, 1988;
Hill and Farkas-Himsley, 1991.) obtained from certain non-lactic acid bacteria (colicins from E. coli, vibriocins from V. cholera and pyocins from P. aeruginosa) (Farkas-Himsley et al., 1975; Farkas-Himsley and Cheung, 1976; Farkas-Himsley and Musclow, 1980) under specific growth conditions (Farkas-Himsley and Yu, 1985), contained materials which were active on various malignant cells, both in vitro (Farkas-Himsley, 1980; Farkas-Himsley et al., 1975; Farkas-Himsley and Cheung, 1976) and in vivo (Hill and Farkas-Himsley, 1991). The PPBs demonstrated selective killing characteristic, differentiating malignant from normal cells (Farkas-Himsley, 1980; Musclow et al., 1987). These authors also noted that the malignant cells which interacted with PPBs contained less DNA than the control cells not treated with PPBs (Farkas-Himsley and Yu, 1985). It was also shown that PPBs interacted with the cell surface, possibly via transferrin receptors (Farkas-Himsley and Musclow, 1986). And finally, they reported that PPBs most likely belonged to the group of proteins that interact with external cell surface receptors and are able to signal the activation of endonucleolytic processes. This supported the hypothesis that PPBs cause programmed cell death by apoptosis (Farkas-Himsley et al., 1992) .
However, the partially purified bacteriocins studied were rather ~~crude" preparations and it possible that contaminating materials (e.g. endotoxins) may have been the cause of variability in the results, primarily for the in vivo experiments. It was recognized that much better purification of the bacteriocins would be required before establishing more definitive conclusions (Fumorola, 1978;
Fumorola et al., 1977). In the case of the highly purified pediocin PA-1 preparation tested herein, the results obtained are noticeably much more valuable due to the quality and the purity of the pediocin PA-1 preparation used.
Further, some bacteriocins can be toxic to mammalian cells (Murinda et al., 2003). Thus, some bacteriocins often intended for use as biopreservatives need to be evaluated for toxicity to mammalian cells.
In contrast, LAB and products derived therefrom are generally considered safe. Indeed, studies carried out with nisin A and pediocin PA-1/AcH have indicated that both bacteriocins are nontoxic to laboratory animals and humans when used at the recommended levels. As such, the uses of LAB-derived bacteriocins described herein provide the advantage of being both safe and having anticancer activity.
In the present study, natural pediocin (e. g.
produced by Pediococcus sp.) showed anticancer activity whereas the recombinant pediocin produced by Pichia sp.
showed no activity. The latter observation is consistent with previous results showing the absence of biological activity for recombinant pediocin PA-1 (Example 2).
Example 4 - Production of recombinant pediocin PA-1 in 5 Escherichia coli Strains, plasmids and culture conditions. The sources and relevant genotypes of bacterial strains, as well as the plasmids used in this study are listed in Table I.
Escherichia coli DHSa, used for standard cloning procedures, 10 and the Origami (DE3) cell line, used for gene expression experiments, were grown in Luria-Bertani (LB) broth (1.0o tryptone, 1.0% NaCl, 0.5o yeast extract, pH 7.0).
Transformants of E.coli were selected onto LB medium supplemented with ampicillin (60 ~g/ml). Pediococcus 15 acidilactici PAC 1.0, the producing strain of pediocin PA-1, and Pediococcus pentosaceus FBB63, used as indicator strain, were grown in Lactobacilli MRS broth (Oxoid) for 18h at 37°C.
Cloning of pedA and plasmid construction. In vitro DNA manipulations (digestion, ligation, transformation) for 20 cloning in E. coli were performed as described by Sambrook et al. (1989). A DNA fragment encoding the mature domain of pediocin PA-1 was obtained by polymerase chain reaction (PCR) amplification of pSRQll DNA isolated fram Pediococcus acidilactici PAC 1.0 using the QIAprepTM Spin Miniprep Kit 25 protocol (QIAgen) with an alkaline lysis procedure (2001 of a cold solution containing 50mM glucose, lOmM EDTA, 25mM Tris pH 8.0 and 4mg/ml of lysozyme (Sigma) were added after step 3). The sequence of the 5' primer used for amplification (5'-AAC CCC AGA TCT CGA CGA CGA CAA GAA ATA CTA CGG TAA TGG G-3' 30 [SEQ ID NO: 6]) begins with AACCCC nucleotides clamp followed by a BglII restriction enzyme site (AGATCT), the enterokinase cleavage sequence (CGACGACGACAAGAA [SEQ ID N0: 7]) and ends with a 18 nucleotide sequence complementary to the first nucleotides of the pedA gene encoding for the mature peptide form. The 3' primer (5'-CCC GGG CTC GAG CTA TTA TCA GCA TTT
ATG ATT ACC TTG ATG TCC A-3' [SEQ ID NO: 8]) contains CCCGGG
nucleotides clamp, followed by an XhoI restriction enzyme site (CTCGAG), the stop colons and ends with a 25 nucleotide sequence complementary to the final eight colons of the pedA
gene. PCR amplification was performed using 40U of Deep VentTM
(exo-) DNA polymerase (New Englands Biolabs) per ml, 1.35 pg of pSRQll template per ml, 1.25mM of each nucleoside triphosphate, and 2 ~g of each primer per ml. PCR was performed to amplify DNA with a hot start at 96°C for 1 min and, then, 30 cycles of amplification (96°C, 30s for strand denaturation; 60°C, 30s, for primer annealing and 72°C, 60s, for primer extension) followed by a final extension at 72°C
for 1 min. The PCR product was purified using the QIAquickTM
PCR Purification Kit Protocol (QIAgen) and digested with BglII and XhoI restriction endonucleases (New England Biolabs). The resulting fragment was purified by agarose gel electrophoresis using the QIAex IITM agarose gel extraction kit (QIAgen) and ligated with T4 DNA Ligase (New England Biolabs) between the BglII and XhoI restriction sites within the pET32b vector. pET32b was pre-digested with the same enzymes. Ligation mixtures were transformed into competent E.coli DHSa cells employing the CaCl2 approach. The pET32b-pedA expression plasmid, isolated using the QIAprepTM Spin Miniprep Kit protocol (QIAgen), was identified by restriction enzyme digestion with XbaI/XhvI (New England Biolabs).
Vectors (pET32b and pET32b-pedA) were transferred into E.coli Origami (DE3) cells. Transformants were selected on Luria Bertani (LB) medium containing ampicillin (60 ~g/ml). The pET32b vector and the pET32b-pedA expression plasmid were isolated using the QIAprepTM Spin Miniprep Kit protocol (QIAgen). The pedA gene region was confirmed by double-stranded DNA sequencing with AmpliTaqTM DNA polymerase (ABI
PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit) using an ABI 3777XL DNA Sequencer (Applied Biosystems). For PCR sequencing, the sequence of the 5' primer used for amplification was (5'-TTC CTT TCG GGC TTT GTT AGC AGC-3' [SEQ
ID N0: 9]) and the sequence of the 3' primer was (5'-TAA ATT
CGA ACG CCA GCA CAT GGA-3' [SEQ ID N0: 10]). These primers corresponded to nucleotide sequences complementary to the upstream and downstream regions of the pedA gene to confirm that its position was in frame with the thioredoxin gene. PCR
reaction products were purified using Centri-SepTM columns (Applied Biosystems) prior to sequencing.
Expression of pediocin PA-1 in E.coli.
Transformants (clone Bl) of E.coli Origami (DE3), stored in 15% glycerol kept at -80°C (0.7 ml), were grown in 2 separate shake flasks of 2L, each with 500 ml of LB medium supplemented with ampicillin ;100 ~g/ml) until the culture reached an OD600 of 0.6-0.8 (approximately 7h). Protein expression was induced by addition of isopropyl ~-D-thiogalactoside (IPTG, Sigma) to a final concentration of 20 ~M. The culture was harvested four hours after induction by centrifugation (30008, 25 min, 4°C). The cell pellets were stored frozen at -20°C prior t.o analysis.
Preparation of cleared cell lysates. Cell lysates were prepared using frozen cells from one liter of culture.
Cells were resuspended in 100 ml of 50 mM sodium phosphate buffer, pH 8.0, containing 300 mM NaCl. The mixture was homogenized using a high-pressure homogenizer (Microfluidics International Corporation, Newton, MA) to disrupt the cells.
Cell breakage, done on ice, was initially performed using a resting pressure of 60psi (0.4MPa) corresponding to an internal pressure of 17000psi (117MPa) and it was repeated 3 times. The resulting cell lysate was centrifuged at 140008 for 30 min at 4°C to remove the insoluble fraction. Cleared cell lysate was filtered using a 0.45~m, low protein binding membrane (Cellulose acetate, Corning) and stored at -20°C
until needed.
Affinity purification of fusion protein under native conditions. Fusion protein (Trx-pedA) present in the cleared cell lysate was captured using a Ni-NTA agarose resin (QIAgen). The VL11 X 250 Amicon column was packed with lOml of resin and connected to a GradiFracTM Chromatography system integrated with an UV1-detector (UV lamp, OD280 nm, Amersham). The column was equilibrated with 10 CV (column volume) of 50mM sodium phosphate buffer, 300 mM NaCl, pH 8.0 (Buffer A). Cleared cell lysate solution (100 ml) was applied to the column at a rate of 30b cm/h, then, the column washed with Buffer A. The fusion protein was eluted with Buffer A
containing 250mM imidazole (ICN Biomedicals, Inc.).
Concentration and diafiltration. Fractions containing Trx-pedA were pooled and concentrated in a 350m1 Stir Cell system (Amicon) using a 3kDa (cut-off) regenerated cellulose membrane (YM3, Diaflo ultrafiltration membrane, Amicon) and diafiltered against 20mM Tris-HCl, 50mM NaCl, 2mM
CaCl2 buffer, pH 7.4 (cleavage buffer).
Site-specific cleavage of Trx-pedA using recombinant enterokinase. The retentate (26 ml) obtained after the concentration step was treated with 80U of recombinant enterokinase (rek, Novagen) overnight at room temperature under gentle rotational agitation (Adams Nutator). The reaction mixture was centrifuged (5 min, 18118 at 20°C) and supplemented with NaCl to reach a concentration of 0.5M. The pH was adjusted with HC1 (0.1N) to 5.0 prior to hydrophobic interaction chromatography (HIC).
Hydrophobic interaction chromatography. The retentate after recombinant enterokinase treatment, which contained biologically active pediocin PA-l, was applied to an Octyl Sepharose CL-4B hydrophobic interaction column (HR5/5, 1 ml CV, Amersham) using a GradiFrac system as mentioned above (Example 1). The column was equilibrated with 5 mM ammonium acetate buffer, pH 5.0, (Buffer B) containing 0.5 M NaCl. The retentate was applied to the column at 306 cm/h, washed with the same buffer (Buffer B + 0.5 M NaCl) followed by another wash with Buffer B. Pediocin PA-1 was eluted with Buffer B containing 50% (v/v) acetonitrile. After removal of the acetonitrile by evaporation (Rotavapor, Buchi), the preparation was loaded onto a semi-preparative reversed-phase HPLC column.
Semi-preparative HPLC purification. The active recombinant pediocin PA-1 fraction eluated from the Octyl-Sepharose column was loaded onto a C18 reversed-phase column (Semi-prep column CSC-Inertsil 150A/ODS2, 5 um, 25 x l.Ocm) and purified by high-pressure liquid chromatography (Waters Millennium32, Waters Scientific, Mississauga, Ontario, Canada). The system was equipped with a Waters 996 Photo Diode Array detector, a Waters 600E solvent delivery pump, a Waters 717 autosampler, and a Waters temperature control module (TCM). A method incorporating a 10 minute non-linear gradient (curve profile number 5) going from 24% (v/v) acetonitrile in 5 mM HCl to 600 (v/v) acetonitrile in 5 mM
HC1 was utilized. The sample was eluted at a flow rate of 3 ml/min with a column temperature of 39°C. The natural (used as standard) and recombinant pediocin PA-1 peak appeared at a retention time of 6 min, corresponding to an acetonitrile concentration of 510 (v/v). Active fractions were pooled and concentrated with a 50 ml Stir Cell system (Amicon) using a 1 kDa (cut-off) regenerated cellulose membrane (YM1, Diaflo ultrafiltration membrane, Amicon) and diafiltered against water (HPLC grade). The retentate was freeze-dried (Flexi-dry, FTS Systems Inc.) and kept at 4°C under a NZ atmosphere.
Detection of pedioci_n PA-1. Purification was 5 followed using a non-competitive indirect ELISA method (Martinez et al. 2000). Microtiter plate wells (Maxisorp, Nunc) were coated with 100 ~l samples diluted in CB (CB =
Coating Buffer: 0.1 M sodium carbonate-bicarbonate buffer, pH
9.6). The plates were incubated overnight at 4°C, blocked for 10 1h at 37°C with 300 ~1 of to (w/v) ovalbumin (Sigma, grade III) in PBS (phosphate-buffered saline O.OlM, pH 7.4) and washed with 0.050 Tween 20 in PBS. Then, 50 ~l of polyclonal antibodies against pediocin PA-1 (antiserum provided by Professor P. E. Hernandez; Martinez et al. 1998) diluted 1000 15 times in PBS were added and the plates incubated for 1h at 37°C. Goat anti-rabbit IgG-HRP (Horseradish Peroxidase) (Biorad) diluted 500 times in ovalbumin solution (lo (w/v) in PBS; blocking solution) was added and the complex was revealed by adding 100 ~l of ABTS (2,2'-azino-bis(3-20 ethylbenzthiazoline-6-sulphonic acid) substrate (Sigma).
Absorbance was read at 405 nm using a SPECTRAFluor Plus Spectrophotometer (TECAN Austria Gmbh, Grodig, Austria).
Activity test of pediocin PA-1. Samples were analyzed by agar spot test on MRS agar medium (Parrot et al.
25 1990). A MRS 1.5o agar plate (20 ml) was covered with 5m1 of soft agar (0.8% (w/v) agar) containing a MRS-grown overnight culture of the indicator strain Pediococcus pentosaceus (adjusted to an optical density of 0.1 at 600 nm, Beckman DU
640 Spectrophotometer). Samples were filtered using a 0.22 ~m 30 membrane (Syringe Driven Filter Unit, Millex-HV, 4mm) prior to addition of 5 ~l onto the surface of the soft agar. The plates were incubated for 18h at 37°C and examined for growth inhibition zones.
Biological activity of the recombinant pediocin PA-1 was also analyzed after Trx-PedA cleavage using the agar spot test method (Parrot et a1.1990). Table 2 shows the dish overlay results. An inhibition zone of growth was observed for section 1 corresponding to the natural pediocin PA-1 standard (Example 1). Biological activity was not detected for the uncleaved Trx-pedA. A very marked inhibition zone was noted for the recombinant ped:iocin PA-1 after cleavage by the enterokinase, which was comparable to that observed with natural pediocin PA-1.
Table 2 - Measurements of natural and recombinant pediocin activity using the dish overlay assay Type of pediocin used Inhibition of growth of Pediococcus pentosaceus Natural ~+++
Recombinant uncleaved Recombinant cleaved I+++
Throughout this application, various references are referred to describe more fully the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.
REFERENCES
Baguley, B. C. and Marshall, E. S. (2004) In vitro modelling of human tumour behaviour in drug discovery programmes.
Eur J Cancer. 40: 794-801.
Baker, M. A., Maloy, W. L., Zasloff, M. and Jacob, L. S.
(1993) Anticancer efficacy of magainin 2 analogue peptides. Cancer Res. 53: 3052-3057.
Bhunia, A. K., Johnson, M. C. et Ray, B. (1988) Purification, characterization and antimicrobial spectrum of a bacteriocin produced by Pediococcus acidilactici. J Appl Bacteriol. 65(4) . 261-268.
Breukink, E. and de Kruijff, B. (1999) The lantibiotic nisin, a special case or not?. Biochim Biophys Acta. 1462: 223 234.
Chen, J., Falla, T. J., Liu, H., Hurst, M. A., Fujii, C. A., Mosca, D. A., Embree, J. R., Loury, D. J., Radel, P. A., Chang, C. C., Gu, L. and Fiddes, J. C. (2000) Development of protegrins for the treatment and prevention of oral mucositis: Structure-activity relationships of synthtic protegrin analogues.
Biopolymers (Peptide Science). 55:88-98.
Crescenzi, O., Guerrini, R., Picone, D., Salvadori, S., Tancredi, T., Temussi, P. A. (2000) Solution structure of novacistatin, a new peptide analgesic. Biopolymers.
53:257-264.
Farkas-Hiinsley, H. (1988) Sensitivity of various malignant cell lines to partially purified bacteriocins: inherent and proliferative dependance. Microbios Lett. 39: 57-66.
Farkas-Himsley, H. (1980) Sensitivity to bacteriocins of murine leukaemias with varying oncogenic potency.
Microbios Lett. 15:89-96.
Farkas-Himsley, H., Cheung, R. (1976) Bacterial proteinaceous products (bacteriocins) as cytotoxic agents of neoplasia. Cancer Res. 36(10): 3561-3567.
Farkas-Himsley, H., Cheung, R. and Tompkins, W. A. F. (1975) Selective antitumor agents: Bacteriocins from Gram-negative bacteria. IRCS Med Sci. 3: 148 Farkas-Himsley, H. and Musclow, C. E. (1980) Bacteriocins in laboratory diagnosis of leukemic cells. IRCS Med Sci. 8:
497-498.
Farkas-Himsley, H. and Musclow, C. E. (1986) Bacteriocin receptors on malignant mammalian cells: Are they transferrin receptors?. Cell Mol Biol. 35(5): 607-617.
Farkas-Himsley, H. and Yu, H. (1985) Purified colicin as cytotoxic agent of neoplasia: Comparative study with crude colicin. Cytobios. 42: 193-207.
Farkas-Himsley, H., Zhang, Y.-S., Yuan, M and Musclow, C. E.
(1992) Partially purified bacteriocin kills malignant cells by apoptosis: programmed cell death. Cell Mol Biol. 38(6): 643-651.
Fumarola, D. (1978) Bacteriocins as cytotoxic agents against tumors: The role of possible contaminants. Boll ist sieroter Milan. pp. 101-102.
Fumarola, D., Bello,P., Palma, R., Miragliotta, G. and Panaro, A. (1977) Bacteri.ocins as cytotoxic agents in experimental neoplasm: considerations on the role of possible contaminants. Giornale di Batteriologica, Virologica ed Immunologia. 70 (1-6): 87-93.
Gaussier, H., Lavoie, M. and Subirade, M. (2003) Conformational changes of- pediocin in an aqueous medium monitored by Fourier transform infrared spectroscopy . A
biological implication. Int J Biol Macromol. 32: 1-9.
Guder, A., Wiedemann, I. and Sahl, H-G. (2000) Posttranslationally modified bacteriocins- The lantibiotics. Biopolymers (Peptide Science). 55: 62-73.
Hancock, R. E. W. (1997). Peptides antibiotics. Lancet 349 :418-422.
Hancock, R. E. W. and Lehrer, R. (1998) Cationic peptides: a new source of antibiotics. Tibtech. 16: 82-88.
Henderson, J. T., Chopko, A. Z. and van Wassenaar, P. D.
(1992) Purification and primary structure of pediocin PA-1 produced by Pediococcus acidilactici PAC 1Ø Arch Biochem Biophys. 295(1): 5-12.
Hill, R. P. and Farkas-Himsley, H. (1991) Further studies of the action of a partially purified bacteriocin against a murine fibrosarcoma. Cancer Research. 51: 1359-1365.
Jaynes, J. M., Julian, G. R., Jeffers, G. W., White, K. L.
and Enright, F. M. (1989) Peptide Res. In vitro cytocidal effect of lytic peptides on several transformed mammalian cell lines. 2: 157-160.
Johnsen, L., Fimlan, G., Eijsink, V, and Nissen-Meyer, J.
(1998) Engineering increased stability in the antimicrobial peptide pediocin PA-1. Appl. Env.
Microbiol. 66(11): 4798-4802.
Luber, A. D. and Hardy, W. D. (2001) Clinical considerations in therapeutic drug monitoring. The body: an AIDS and HIV information resource. HIV Newsline. 7(1):
http://www.thebody.com/hivnews/newsline/feb2001/optimal2 .html.
Marneros, A. G. and Bjorn, O. R. (2001) The role of collagen-derived proteolytic fragments in angiogenis. Matrix Biology. 20: 337-345.
Marshall, S. H. and Arenas, G. (2003) Antimicrobial peptides:
A natural alternative to chemical antibiotics and a potential for applied biotechnology. Elect J Biotechnol.
6(2): 271-284.
Mi-Kyung, S., Woo, S.-G., Jang, J-S., Kim, J.-H., Kim, H.-Y., Hong, S.-G., L~e, B.-W., Park, M.-H. and Chung, K. S.
5 (2003) Immunostimulating and anti-cancer effects of Pediococcus pentosaceus EROM101 isolated from Korea. Kor J Microbiol Biotechnol. 31(4): 355-361.
Miller, K. W., Schamber, R., Osmanagaoglu, O. and Bibek, R.
(2000) Isolation and Characterization of pediocin AcH
10 chimeric protein mutants with altered bactericidal activity. Appl. Env. Res. 64(6): 1997-2005.
Moors, A. J., Devine, D. A. and Bibby, M. C. (1994) Preliminary experimental anticancer activity of cecropins. Peptide Res. 7(5): 265-269.
15 Murinda, S. E., Rashid, K. A. and Roberts, R. F. (2003) In vitro assessment of the cytotoxicity of nisin, pediocin, and selected colicins on Simian Virus 40-transfected human colon and Vero monkey cells with trypan blue staining viability assays. J Food Protect. 66(5): 847-20 853.
Musclow, C. E., Farkas-Himsley, H., Wetzman, S. S. and Herridge (1987) Acute lymphoblastic leukemia of childwood monitored by bacteriocin and flowcytometry.
Eur J Cancer Clin Oncol. 23(4) . 411-418.
25 Nes, I. F. and Holo, H. (2000). Class II antimicrobial peptides from lactc acid bacteria. Biopolymers (Peptide Science). 55: 50-61.
O'Brien, J., Wilson, I., Orton, T. and Pognan, F. (2000) Investigation of the alamar blue (resazurin) fluorescent 30 dye for the assessment of mammalian cell cytotoxicity.
Eur J Biochem. 267: 5421-5426.
Ohsaki, Y., Gazdar, A. F., Chen, H.-C. and Jonhson, B. E.
(1992) Antitumor activity of magainin against human lung cancer cell lines. Cancer Res. 52: 3534-3538.
Reisch, M. S (2002) C & EN Northeast news bureau.
Rodriguez, J. M., Martinet, M. I. and Kok, J. (2002) Pediocin PA-l, a wide-spectrum bacteriocin from lactic acid bacteria. Crit Rev Food Sci. 42(2): 91-121.
Ross, R. P., Galvin, M., McAuliffe, O., Morgan, S. M., Ryan, M. P., Twomey, D. P., Meaney, W. J. and Hill, C. (1999) Developing applications for lactococcal bacteriocins.
Antonie van Leeuwenhoek. 76: 337-346.
Sharma, S. V. (1992) Melittin resistance: a counterselection for ras transformation. Oncogene. 7: 193-201.
Uteng, M., Hauge, H. H., Brondz, I., Nissan-Meyer, J. and Fimland, G. (2002) Rapid two-step procedure for large-scale purification of pediocin-like bacteriocins and other cationic antimicrobial peptides from complex culture medium. Appl Environ Microb. 68(2) . 952-956.
Wachsman, M. B., Farias, M. E., Takeda, E., Sesma, F., de Ruiz Holgado, A. P., de Torres, R. A. and Coto, C. E.
(1999) Antiviral activity of enterocin CRL35 against herpesviruses. Int J Anti.microb Ag. 12: 293-299.
Wachsman, M. B.; Castilla, V.; de Ruiz Holgado, A. P.; de Torres, R. A.; Sesma, F. and Coto, C. E. (2003) Enterocin CRL35 inhibits late stages of HSV-1 and HSV-2 replication in vitro. Antiviral Research. 58: 17-24.
Winder, D., Gunzburg, W. H., Erfle, V. and Salmons, B. (1998) Expression of antimicrobial peptides has an antitumour effect in human cells. Biochemical and Biophysical Research communications. 242: 608-612.
Gaussier, H., H. Morency, M. C. Lavoie, and M. Subirade.
2002. Replacement of triofluoroacetic acid with HCl in the hydrophobic purification steps of pediocin PA-l: a structural effect. Appl. Environ. Microb. 68: 4803-4808.
Parrot, M., Caufield, P. W. and Lavoie, M. C. (1990) Preliminary characterization of four bacteriocins from Streptococcus mutans. Can J Microbiol. 36: 123-130.
Rodriguez, J. M., M. I. Martinet, and J. Kok. 2002. Pediocin PA-l, a wide-spectrum bacteriocin from lactic acid bacteria. Crit. Rev. Food Sci. 42: 91-121.
PREVENTION OR TREATMENT OF CANCER
FIELD OF THE INVENTION
The invention relates to the use of bacteriocins and compositions comprising such bacteriocins for the treatment and/or prevention of cancer. The invention also relates to the use of bacteriocins and compositions comprising such bacteriocins for inhibiting proliferation of cancerous cells. The invention particularly relates to bacteriocins derived from lactic acid bacteria and compositions comprising such bacteriocins.
BACKGROUND OF THE INVENTION
Conventional chemotherapeutic agents are usually not specific towards cancerous cells and halt the progression of any dividing cells. As such, these drugs are highly cytotoxic and can cause serious side effects (loss of hair, loss of intestine villosities, depletion of immune cells, etc.) and can impair significantly the quality of life of the patient (infertility, depression, etc.). Consequently, their use if often limited by the amount one can tolerate.
In addition, the use of conventional chemotherapeutic agents is also known to cause drug resistance in cancerous cells, and often multi-drug resistance. Hence, clinicians have to readjust, over the course of the treatment, the dosage and/or the composition of chemotherapeutic cocktails to take into account the newly acquired drug resistance phenotype of the cancerous cells.
Further, to date, many cancers cannot be treated and represent a significant percentage of mortality.
There is thus a need for improved chemotherapeutic agents. These agents may be more effective, more selective towards cancerous cells, may riot cause drug resistance and/or may be used to halt the progression of multi-drug resistant cancerous cells.
SUI~1ARY OF THE INVENTION
The present invention relates to the use of a bacteriocin, and more particularly to the use of a bacteriocin for the treatment and prevention of cancer.
In a first aspect, the present invention provides a method of preventing or treating cancer in an animal, the method comprising administering to the animal an agent selected from the group consisting of (a) a bacteriocin derived from a lactic-acid bacteria, and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier (or any combinations thereof).
In an embodiment, the agent is cytotoxic to the cancerous cell of the cancer. In another embodiment, the agent is administered through or adapted for administration through a route selected from the group consisting of intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal, intratumoral and topical. In yet another embodiment, the agent is the bacteriocin and, in a further embodiment, the bacteriocin is substantially pure. In another embodiment, the bacteriocin is a recombinant bacteriocin and, in a further embodiment, the recombinant bacteriocin is produced in a prokaryotic host. In yet another embodiment, the bacter_iocin is selected from the group consisting of bavaricin, helveticin, acidocin, lactocin, lactacin, lacticin, nisin, leucocin, lactococcin, pediocin, curvaticin, curvacin, mutacin, mesentericin, plantaricin, streptin and sakacin. In another embodiment, the bacteriocin is pediocin arid, in a further embodiment, the bacteriocin is pediocin PA-1. In yet another embodiment, the pediocin PA-1 comprises an amino acid sequence substantially identical to the sequence set forth in SEQ ID NO: 2 or a fragment thereof. In yet a further embodiment, the bacteriocin is derived from a lactic acid bacteria species selected from the group consisting of Streptococcus spp., Lactococcus spp., Lactobacillus spp., Pediococcus spp., Leuconostoc spp., Bifidobacterium spp. and Enterococcus spp.
In an embodiment, the bacteriocin is derived from Pediococcus spp, in a further embodiment, the bacteriocin is derived from Pediococcus acidilactici and, in yet a further embodiment, the bacteriocin is derived from Pediococcus acidilactici PAC
1Ø
In an embodiment, the agent is the above-mentioned composition. In another embodiment, the carrier is selected from the group consisting of a pharmaceutically acceptable carrier and a nutraceutically acceptable carrier and, in a further embodiment, the carrier is a nutraceutically acceptable carrier. In yet another embodiment, the agent is administered through or adapted for administreation through an oral route. In another embodiment, the composition is substantially free of contaminants from the lactic acid bacteria from which said bacteriocin is derived. In an embodiment, the nutraceutically acceptable carrier is a food product, in a further embodiment, the food product is a fermented food product and, in yet a further embodiment, the fermented food product is a fermented milk. In another embodiment, the animal is a mammal and, in yet a further embodiment, the mammal is a human. In an embodiment, the cancer affects an organ, tissue, cell or system selected from the group consisting of bone, soft tissue, brain, spinal cord, breast, adrenal gland, pancreas, parathyroid, pituitary, thyroid, anus, colon, rectum, esophagus, gallbladder, stomach, liver, cervix, endometrium, uterus, fallopian tube, ovaries, vagina, vulva, larynges, oropharynges, immune cell, immune system, lung, lymph node and plasma cell. In another embodiment, the cancer is lung cancer and/or colon cancer.
In another aspect, the present invention provides use of an agent selected from the group consisting of (a) a bacteriocin derived from a lactic acid bacteria and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier for the prevention or treatment of cancer in an animal. In a further aspect, the present invention provides use of an agent selected from the group consisting of (a) a bacteriocin derived from a lactic acid bacteria and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier for the preparation of a medicament for the prevention or treatment of cancer in an animal. In an embodiment, the agent used is the agent described herein. In yet another embodiment, the animal is the animal described herein. In another embodiment, the cancer treated or prevented is the cancer described herein.
In yet another aspect, the present invention provides a bacteriocin derived from a lactic acid bacteria for use in the prevention or treatment of cancer in an animal.
In still a further aspect, the present invention provides a composition comprising (i) a bacteriocin derived from a lactic acid bacteria and (ii) a carrier for use in the prevention or treatment of cancer in an animal.
In still another aspect, the present invention provides a package comprising (a) an agent selected from the group consisting of (i) a bacteriocin derived from a lactic acid bacteria and (ii) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier and (b) instructions for the use of said agent in the treatment or prevention of cancer in an animal. In an embodiment, the agent used is the agent described herein. In yet another embodiment, the animal is the animal described herein. In 5 another embodiment, the instructions indicate the use of the agent for the treatment or prevention of a cancer described herein.
In still another aspect, the present invention provides a method of inhibiting proliferation of a cancerous cell in an animal, said method comprising administering to said animal a bacteriocin derived from a lactic acid bacteria. In an embodiment, the bacteriocin used is the bacteriocin described herein. In yet another embodiment, the animal is the animal described herein. In another embodiment, the cancer treated or prevented is the cancer described herein.
In another aspect, the present invention provides a method of inhibiting proliferation of a cancerous cell, said method comprising contacting said cell with a bacteriocin derived from a lactic acid bacteria. In an embodiment, the bacteriocin used is the bacteriocin described herein. In yet another embodiment, the animal is the animal described herein. In another embodiment, the cancer treated or prevented is the cancer described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. Pediococcus acidilactici bacteriocin complete coding sequence (SEQ ID NO: 1, GenBank accession number M83924) Figure 2. Pediocin PA-1 polypeptide sequence (SEQ ID N0: 2, GenBank accession number AAA25559) DETAILED DESCRIPTION OF THE INVENTION
In a first aspect, the invention relates to a method of preventing and/or treating cancer. As used herein the terms "preventing", "prevention", "treating" and "treatment" relate to the retardation or inhibition of the onset of a cancer and/or progression of a cancer (e. g.
formation and growth of a primary tumor, dissemination of metastases, growth of metastases, involvement of lymph nodes etc.). The invention also relates to the inhibition of proliferation of cancerous cells. The term "cancer" as used herein relates to the malignant growth of cells. The cancer may be restricted to one organ, tissue or cell type or may be disseminated throughout the body and affect several organs, tissues or cell types. In an embodiment, the cancer may affect bones (e. g. sarcoma, osteosarcoma, rhabdomyosarcoma), brain or spinal cord (e. g. oligodendroglioma, ependymoma, meningioma, lymphoma, schwannoma, medulloblastoma), breasts (e.g. carcinoma in situ such as lobular carcinoma in situ and ductal carcinoma in situ, stage I, II, II and IV carcinoma), endocrine system (e. g. adrenal cancer or pheochromocytoma, pancreatic cancer, parathyroid cancer, pituitary tumors, thyroid cancer), gastrointestinal system (e. g. carcinoma, adenocarcinoma, anal cancer, colon cancer, rectal cancer, esophageal cancer, gallbladder cancer, gastric cancer, liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, hemangiosarcoma and hepatoblastoma, pancreatic cancer, cancer of the small intestine), reproductive system (e. g. cervical cancer, endometrial cancer, uterine cancer, fallopian tube cancer, gestational trophoblastic disease and choriocarcinoma, ovarian cancer, vaginal cancer, vulvar cancer), head and neck (e. g. laryngeal cancer, oropharyngeal cancers, parathyroid cancer, t=hyroid cancer), immune system (e.g acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia, myeloproliferative disorders), lungs (e. g. mesothelioma, non-small cell lung cancer, small-cell lung cancer), lymph nodes (e. g. AIDS-related lymphoma, cutaneous T-cell lymphoma/mucosis fungoides, Hodgkin's disease, non-Hodgkin's disease), and plasma (e. g. multiple myeloma).
According to another aspect, the invention also provides a method of preventing or treating cancer in an animal. In an embodiment, the animal is a mammal, and, in a further embodiment the mammal is a human. In another embodiment, the methods described herein can be used to treat other animals or other mammals (such as a cat, a dog or a horse).
According to yet another aspect, the methods described herein comprise administering an agent to said animal. In an embodiment, the agent is cytotoxic to cancerous cells. As used herein, the term "cytotoxic"
relates to the ability of the agent to halt or retard the growth of cancerous cells or to induce the death of such cells. In another embodiment, the agent may be administered through a route selected from the group consisting of intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal, intratumoral and topical. In an embodiment, the agent may be administered alone or in combination with other chemotherapeutic agents. In another embodiment, the agent may be administered in conjunction (before, simultaneously or after) with a radiation therapy.
The invention also provides a method of treating or preventing cancer, the method comprising administering an agent selected from the group~consisting of (a) a bacteriocin derived from a lactic acid bacteria and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier. As used herein the term "bacteriocin" relates to a polypeptide produced by a microbial cell (e.g. a bacteria), wherein such polypeptide possesses microbicidal (e. g. bacteriocidal) activity. The microbicidal (e. g.
bactericiodal) activity of a bacteriocin can be measured using several techniques known by those skilled in the art, such as the agar spot test (see Example 4). The presence of a bacteriocin can also be assessed with other standard methods such as Western blotting, 2D electrophoresis, capillary electrophoresis, imaging techniques (e. g. specific antibodies coupled to immunof:luorescent compounds or an enzyme that enables colorimet:ric visualisation), ELISA, RIA
and protein micro-array.
In an embodiment, the above-mentioned bacteriocin is derived from a lactic acid bacteria (LAB). Such bacteriocins include, but are not limited to, bavaricin, helveticin, acidocin, lactocin, lactacin, lacticin, nisin, leucocin, lactococcin, pediocin, curvaticin, curvacin, mutacin, mesentericin, plantaricin, streptin and sakacin.
In an embodiment, the bacteriocin is pediocin and, in a further embodiment, the bacteriocin is pediocin PA-1.
Pediocin AcH and pediocin PA-1 are used herein interchangeably. In yet another embodiment, pediocin PA-1 has a sequence substantially identical to the sequence set forth in Figure 2 (e.g. SEQ ID NO: 2) or is encoded by a nucleotide sequence capable of encoding a polypeptide substantially identical to the sequence set forth in Figure 2 (e. g. SEQ ID NO: 1). In another embodiment, amino acid variants of pediocin (such as those described in Johnsen et al., 2000 and Miller et al., 1998) can also be used in the methods described herein. In another embodiment, the bacteriocins and variants described herein may also retain microbicidal (e.g. bacteriocidal) activity. In an embodiment, the pediocin having a variation in its amino acid sequence with respect to the natural pediocin sequence may have enhanced stability, enhanced microbicidal activity and/or enhanced anti-cancer activity.
Agents of the invention can be prepared, for example, by replacing, deleting, or inserting an amino acid residue of a bacteriocin derived from a lactic acid bacteria, with other conservative amino acid residues, i.e., residues having similar physical, biological, or chemical properties, and screening for biological function. It is well known in the art that some modifications and changes can be made in the structure of a polypeptide without substantially altering the biological function of that peptide, to obtain a biologically equivalent polypeptide. The peptides, ligands and domains of the present invention also extend to biologically equivalent peptides, ligands and domains that differ from a portion of the sequence of novel ligands of the present invention by conservative amino acid substitutions.
As used herein, the term "conserved amino acid substitutions"
refers to the substitution of one amino acid for another at a given location in the peptide, where the substitution can be made without substantial loss of the relevant function. In making such changes, substitutions of like amino acid residues can be made on the basis of relative similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like, and such substitutions may be assayed for their effect on the function of the peptide by routine testing. In some embodiments, conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydrophilicity value (e. g., within a value of plus or minus 2.0), where the following may be an amino acid having a hydropathic index of about -1.6 such as Tyr (-1.3) or Pro (-1.6)s are assigned to amino acid residues (as detailed in United States Patent No. 4,554,101, incorporated herein by reference): Arg (+3.0); Lys (+3.0); Asp (+3.0); Glu (+3.0);
5 Ser (+0.3); Asn (+0.2); Gln (+0.2); Gly (0); Pro (-0.5); Thr (-0.4); Ala (-0.5); His (-0.5); Cys (-1.0); Met (-1.3); Val (-1.5); Leu (-1.8); Ile (-1.8); Tyr (-2.3); Phe (-2.5); and Trp (-3.4).
In alternative embodiments, conserved amino acid 10 substitutions may be made where an amino acid residue is substituted for another having a similar hydropathic index (e. g., within a value of plus or minus 2.0). In such embodiments, each amino acid residue may be assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics, as follows: Ile (+4.5); Val (+4.2);
Leu (+3.8); Phe (+2.8); Cys (+2.5); Met (+1.9); Ala (+1.8);
Gly (-0.4); Thr (-0.7); Ser (-0.8); Trp (-0.9); Tyr (-1.3);
Pro (-1.6); His (-3.2); Glu (-3.5); Gln (-3.5); Asp (-3.5);
Asn (-3.5); Lys (-3.9); and Arg (-4.5).
In alternative embodiments, conserved amino acid substitutions may be made where an amino acid residue is substituted for another in the same class, where the amino acids are divided into non-polar, acidic, basic and neutral classes, as follows: non-polar: Ala, Val, Leu, Ile, Phe, Trp, Pro, Met; acidic: Asp, Glu; basic: Lys, Arg, His; neutral:
Gly, Ser, Thr, Cys, Asn, Gln, Tyr.
Conservative amino acid changes can include the substitution of an L-amino acid by the corresponding D-amino acid, by a conservative D-amino acid, or by a naturally-occurring, non-genetically encoded form of amino acid, as well as a conservative substit=ution of an L-amino acid.
Naturally-occurring non-genetically encoded amino acids include beta-alanine, 3-amino-propionic acid, 2,3-diamino propionic acid, alpha-aminoisobutyric acid, 4-amino-butyric acid, N-methylglycine (sarcosine), hydroxyproline, ornithine, citrulline, t-butylalanine, t-butylglycine, N-methylisoleucine, phenylglycine, cyclohexylalanine, norleucine, norvaline, 2-napthylalanine, pyridylalanine, 3-benzothienyl alanine, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, penicillamine, 1,2,3,4-tetrahydro-isoquinoline-3-carboxylix acid, beta-2-thienylalanine, methionine sulfoxide, homoarginine, N-acetyl lysine, 2-amino butyric acid, 2-amino butyric acid, 2,4,-diamino butyric acid, p-aminophenylalanine, N-methylvaline, homocysteine, homoserine, cysteic acid, epsilon-amino hexanoic acid, delta-amino valeric acid, or 2,3-diaminobutyric acid.
In alternative embodiments, conservative amino acid changes include changes based on considerations of hydrophilicity or hydrophobic.ity, size or volume, or charge.
Amino acids can be generally characterized as hydrophobic or hydrophilic, depending primarily on the properties of the amino acid side chain. A hydrophobic amino acid exhibits a hydrophobicity of greater than zero, and a hydrophilic amino acid exhibits a hydrophilicity of less than zero, based on the normalized consensus hydrophobicity scale of Eisenberg et al. (J. Mol. Bio. 179:125-142, 1984). Genetically encoded hydrophobic amino acids include Gly, Ala, Phe, Val, Leu, Ile, Pro, Met and Trp, and genetically encoded hydrophilic amino acids include Thr, His, Glu, Gln, Asp, Arg, Ser, and Lys.
Non-genetically encoded hydrophobic amino acids include t-butylalanine, while non-genetically encoded hydrophilic amino acids include citrulline and homocysteine.
Hydrophobic or hydrc>philic amino acids can be further subdivided based on the characteristics of their side chains. For example, an aromatic amino acid is a hydrophobic amino acid with a side chain containing at least one aromatic or heteroaromatic ring, which may contain one or more substituents such as -OH, -SH, -CN, -F, -Cl, -Br, -I, -N02, -N0, -NH2, -NHR, -NRR, -C (0) R, -C (O) OH, -C (0) OR, -C (0) NH2, -C(0)NHR, -C(0)NRR, etc., where R is independently (Cl-C6) alkyl, substituted (Cl-C6) alkyl, (C1-C6) alkenyl, substituted (C1-C6) alkenyl, (Cl-C6) alkynyl, substituted (Cl-C6) alkynyl, (C5-C20) aryl, substituted (C5-C20) aryl, (C6-C26) alkaryl, substituted (C6-C26) alkaryl, 5-20 membered heteroaryl, substituted 5-20 membered heteroaryl, 6-26 membered alkheteroaryl or substituted 6-26 membered alkheteroaryl. Genetically encoded aromatic amino acids include Phe, Tyr, and Tryp, while non-genetically encoded aromatic amino acids include phenylglycine, 2-napthylalanine, beta-2-thienylalanine, 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, 4-chlorophenylalanine, 2-fluorophenylalanine3-fluorophenylalanine, and 4-fluorophenylalanine.
An apolar amino acid is a hydrophobic amino acid with a side chain that is uncharged at physiological pH and which has bonds in which a pair of electrons shared in common by two atoms is generally held equally by each of the two atoms (i.e., the side chain is not polar). Genetically encoded apolar amino acids include Gly, Leu, Val, Ile, Ala, and Met, while non-genetically encoded apolar amino acids include cyclohexylalanine. Apolar amino acids can be further subdivided to include aliphatic amino acids, which is a hydrophobic amino acid having an aliphatic hydrocarbon side chain. Genetically encoded aliphatic amino acids include Ala, Leu, Val, and Ile, while non-genetically encoded aliphatic amino acids include norleucine.
A polar amino acid is a hydrophilic amino acid with a side chain that is uncharged at physiological pH, but which has one bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms.
Genetically encoded polar amino acids include Ser, Thr, Asn, and Gln, while non-genetically encoded polar amino acids include citrulline, N-acetyl lysine, and methionine sulfoxide.
An acidic amino acid is a hydrophilic amino acid with a side chain pKa value of. less than 7. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Genetically encoded acidic amino acids include Asp and Glu. A basic amino acid is a hydrophilic amino acid with a side chain pKa value of greater than 7. Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion. Genetically encoded basic amino acids include Arg, Lys, and His, while non-genetically encoded basic amino acids include the non-cyclic amino acids ornithine, 2,3,-diaminopropionic acid, 2,4-diaminobutyric acid, and homoarginine.
The above classifications are not absolute and an amino acid may be classified in more than one category. In addition, amino acids can be r_lassified based on known behaviour and or characteristic chemical, physical, or biological properties based on specified assays or as compared with previously identified amino acids. Amino acids can also include bifunctional moieties having amino acid-like side chains.
Conservative changes can also .include the substitution of a chemically derivatised moiety for a non-derivatised residue, by for example, reaction of a functional side group of an amino acid. Thus, these substitutions can include compounds whose free amino groups have been derivatised to amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Similarly, free carboxyl groups can be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides, and side chains can be derivatized to form 0-acyl or 0-alkyl derivatives for free hydroxyl groups or N-im-benzylhistidine for the imidazole nitrogen of histidine. Peptide analogues also include amino acids that have been chemically altered, for example, by methylation, by amidation of the C-terminal amino acid by an alkylamine such as ethylamine, ethanolamine, or ethylene diamine, or acylation or methylation of an amino acid side chain (such as acylation of the epsilon amino group of lysine). Peptide analogues can also include replacement of the amide linkage in the peptide with a substituted amide (for example, groups of the formula -C(O)-NR, where R is (C1-C6) alkyl, (C1-C6) alkenyl, (C1-C6) alkynyl, substituted (C1-C6) alkyl, substituted (C1-C6) alkenyl, or substituted (C1-C6) alkynyl) or isostere of an amide linkage (for example, -CH2NH-, -CH2S, -CH2CH2-, -CH=CH- (cis and trans), -C(O)CH2-, -CH(OH)CH2-, or -CH2S0-).
"Homology" and "homologous" refers to sequence similarity between two peptides or two nucleic acid molecules. Homology can be determined by comparing each position in the aligned sequences. A degree of homology between nucleic acid or between amino acid sequences is a function of the number of identical or matching nucleotides or amino acids at positions shared by the sequences. As the term is used herein, a nucleic acid sequence is "homologous"
to another sequence if the two sequences are substantially identical and the functional activity of the sequences is conserved (as used herein, the term "homologous" does not infer evolutionary relatedness). Two nucleic acid sequences are considered substantially identical if, when optimally aligned (with gaps permitted), they share at least about 50%
sequence similarity or identity, or if the sequences share defined functional motifs. In alternative embodiments, sequence similarity in optimally aligned substantially 5 identical sequences may be at least 600, 70%, 750, 800, 850, 900 or 950. As used herein, a given percentage of homology between sequences denotes the degree of sequence identity in optimally aligned sequences. An "unrelated" or "non-homologous" sequence shares less than 40% identity, though 10 preferably less than about 25 o identity, with any of SEQ ID
NOs. 1 and 2.
Substantially complementary nucleic acids are nucleic acids in which the complement of one molecule is substantially identical to the other molecule. Two nucleic 15 acid or protein sequences are considered substantially identical if, when optimally aligned, they share at least about 70o sequence identity. In alternative embodiments, sequence identity may for example be at least 750, at least 800, at least 850, at least 900, or at least 95%. Optimal alignment of sequences for comparisons of identity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith arid Waterman, 1981, Adv. Appl.
Math 2: 482, the homology alignment algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48:443, the search for similarity method of Pearson and Lipman, 1988, Proc. Natl.
Acad. Sci. USA 85: 2444, and the computerised implementations of these algorithms (such as CAP, BESTFIT, FASTA and TFASTA
in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, WI, U.S.A.). Sequence identity may also be determined using the BLAST algorithm, described in Altschul et al., 1990, J. Mol. Biol. 21.5:403-10 (using the published default settings). Software for performing BLAST analysis may be available through the National Center for Biotechnology Information (through the Internet at http://www.ncbi.nlm.nih.gov/). The BLAST algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold. Initial neighbourhood word hits act as seeds for initiating searches to find longer HSPs. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased.
Extension of the word hits in each direction is halted when the following parameters are met: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program may use as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (Henikoff and Henikoff, 1992, Proc. Natl. Acad. Sci.
USA 89: 10915-10919) alignments (B) of 50, expectation (B) of 10 (or 1 or 0.1 or 0.01 or 0.()01 or 0.0001), M=5, N=4, and a comparison of both strands. One measure of the statistical similarity between two sequences using the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. In alternative embodiments of the invention, nucleotide or amino acid sequences are considered substantially identical if the smallest sum probability in a comparison of the test sequences is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
An alternative indication that two nucleic acid sequences are substantially complementary is that the two sequences hybridize to each other under moderately stringent, or preferably stringent, conditions. Hybridisation to filter-bound sequences under moderately stringent conditions may, for example, be performed in 0.5 M NaHP04, 7o sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.2 x SSC/O.lo SDS at 42°C (see Ausubel, et al. (eds), 1989, Current Protocols in Molecular Biology, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3). Alternatively, hybridization to filter-bound sequences under stringent conditions may, for example, be performed in 0.5 M NaHP04, 7o SDS, 1 mM EDTA at 65°C, and washing in 0.1 x SSC/O.lo SDS at 68°C (see Ausubel, et al.
(eds), 1989, supra). Hybridization conditions may be modified in accordance with known methods depending on the sequence of interest (see Tijssen, 1993, Laboratory Techniques in Biochemistry and Molecular Biology -- Hybridization with Nucleic Acid Probes, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York). Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point for the specific sequence at a defined ionic strength and pH.
In another aspect, t=he invention provided methods of using a bacteriocin derived from a lactic acid bacteria (e.g. in the form of a composition or not) to treat or prevent cancer. As used herein, the term "lactic acid bacteria" (LAB) is a class of bacteria that are capable of producing lactic acid. Usually, LAB are gram positive bacteria. In embodiments, some LAB can be used in the preparation (e. g. fermentation) of various food products (such as milk, meat, vegetable and fruit). In embodiments, the lactic acid bacteria species include, but are not limited to Streptococcus spp., Lactococcus spp., Lactobacillus spp., Pediococcus spp., Bifidobacterium spp., Leuconostoc spp, and Enterococcus spp. In an embodiment, the bacteriocin is derived from Pediococcus acidilactici and, in a further embodiment, the bacteriocin is derived from from Pediococcus acidilactici PAC 1Ø
As used herein the term "derived from a LAB" is defined as either produced by a LAB or being of LAB origin but produced by other means (e. g. expressed in another system; e.g. a prokaryotic system, such as E. coli).
In yet another embodiment, the bacteriocin described herein is substantially pure. A compound or agent that is "substantially pure" is separated from the components that naturally accompany it. Typically, a compound is substantially pure when it is at least 600, more generally 750 or over 900, by weight, of the total material in a sample. Thus, for example, a polypeptide that is chemically synthesised or produced by recombinant technology will generally be substantially free from its naturally associated components. A nucleic acid molecule is substantially pure when it is not immediately contiguous with (i.e. covalently linked to) the coding sequences with which it is normally contiguous in the naturally occurring genome of the organism from which the DNA of the invention is derived. A
substantially pure compound can be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid molecule encoding a polypeptide compound; or by chemical synthesis. Purity can be measured using any appropriate method such as column chromatography, gel electrophoresis, HPLC, etc.
In a further embodiment, the agent described herein is substantially free of bacterial contaminants from the lactic acid bacteria (e.g. Pediococcus spp.) from which it is derived. Such contaminants may be cell wall components, organelles (such as the Golgi, endoplasmic reticulum, ribosomes), nuclear components (such as the nuclear wall, the nucleus or the nucleic acid it contains), nucleotides (such as ribonucleotides and/or deoxyribonucleotides), lipids, proteins and protein fragments, etc. In another embodiment, the bacteriocin is isolated/purified from the lactic acid bacteria in which it is produced (refer to the methods described above and in the examples).
The invention also relates to a method of treating or preventing cancer, said method comprising administering a bacteriocin derived from a lactic acid bacteria and/or a composition comprising such a bacteriocin and a suitable carrier. In an embodiment, the bacteriocins (e. g. pediocin) described herein may be modified/adapted to be more resistant (e. g. less degraded) in the presence of gastro-intestinal juices. In an embodiment, the agent may be administered in a way such that the bacteriocin does not come into contact with the gastro-instestinal (GI) tract (e. g. intravenous administration). In another embodiment, the amino acid sequence of the bacteriocin can be modified to increase its stability in the GI tract. Such modifications include, but are not limited to, replacing o-amino acids by z-amino acids.
In yet another embodiment, the agent can be coated with or formulated with a material that enables the rapid and specific delivery of the agent to a specific location in the GI tract, thereby limiting the contact between the bacteriocin and the GI juices. In another embodiment, the bacteriocin can be provided in the form of a food product or a nutraceutical comprising the bacteriocin, such as a fermented food product or a fermented milk. The incorporation of bacteriocins into a food product or nutraceutical may prevent the degradation of the bacteriocins.
5 In various embodiments, the agent described herein, may be used therapeutically in formulations or medicaments to prevent or treat cancer. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of an agent is administered in a pharmacologically acceptable 10 formulation or nutraceutically acceptable formulation, e.g.
to a patient or subject in need thereof. Accordingly, the invention also provides therapeutic compositions comprising a bacteriocin derived from a lactic acid bacteria and a carrier. In an embodiment, the carrier is a pharmaceutically 15 acceptable carrier or a nutraceutically acceptable carrier.
As used herein, the ~~nutraceutically acceptable carrier" is defined as a carrier that is suitable for administration in a nutraceutical. For those skilled in the art, a nutraceutical is defined as any substance that is a food or a part of a 20 food and provides medical or health benefits, including the prevention and treatment of disease. Such products may range from isolated nutrients, dietary supplements and specific diets to genetically engineered designer foods, herbal products, and processed foods such as cereals, soups and beverages. This definition also includes a bio-engineered designer vegetable food, rich in antioxidant ingredients, and a functional food or pharmafood. A nutraceutical is also defined as a product isolated or purified from foods, and generally sold in medicinal forms not usually associated with food and demonstrated to have a physiological benefit or provide protection against or improvement of a disease condition. In an embodiment, the nutraceutically acceptable carrier may be a food product (e. g. soy derivative, milk derivative, meat product, juice, etc.) and, in a further embodiment, it may be a fermented food product. Fermented food products include, but are not limited to, fermented milk products.
In one embodiment, such compositions include a bacteriocin derived from a lactic acid bacteria in a therapeutically or prophylactically effective amount sufficient to treat or prevent cancer in an animal. The composition may be soluble in an aqueous solution at a physiologically acceptable pH.
A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as the prevention or treatment of a cancer (e.g. inhibition or reduction of growth of a primary tumor, inhibition or reduction of implantation or growth of metastases, inhibition or reduction of lymph nodes involvement). A therapeutically effective amount of a bacteriocin derived from a lactic acid bacteria may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the agent to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount"
refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as preventing or inhibiting the rate of cancer onset or progression. A prophylactical:ly effective amount can be determined as described above for the therapeutically effective amount. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions.
As used herein ~~pharmaceutically acceptable carrier" or ~~excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration.
Alternatively, the carrier can be suitable for intravenous, intraperitoneal, intramuscular, sublingual, intratumoral or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage.
The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the :like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, a bacteriocin derived from a lactic acid bacteria can be administered in a time release formulation, for example in a composition which includes a slow release polymer. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems.
Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.
Sterile injectable solutions can be prepared by incorporating the active compound (e. g. a bacteriocin derived from a lactic acid bacteria) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. In accordance with an alternative aspect of the invention, a bacteriocin derived from a lactic acid bacteria may be formulated with one or more additional compounds that enhance the solubility of the bacteriocin.
In accordance with another aspect of the invention, therapeutic compositions of the present invention, comprising an agent (e. g. a bacteriocin derived from a lactic acid bacteria and/or a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier), may be provided in containers or packages (e. g. commercial packages) which further comprise instructions for use of the agent for preventing and/or treating of cancer.
Accordingly, the invention further provides a package (e. g. commercial package) comprising a bacteriocin derived from a lactic acid bacteria or the above-mentioned composition together with instructions for the use of the bacteriocin and/or composition for the prevention and/or treatment of cancer.
The invention further provides use of a bacteriocin derived from a lactic acid bacteria or the above-mentioned composition for the prevention and/or treatment of cancer.
The invention further provides the use of a bacteriocin derived from a lactic acid bacteria for the preparation of a medicament for prevention and/or treatment of cancer.
In yet another aspect, the invention also provides a gene therapy method for treating or preventing cancer.
Nucleic acids encoding a bacteriocin derived from a lactic acid bacteria may be delivered to cells in vivo using methods such as direct injection of DNA, receptor-mediated DNA
uptake, viral-mediated transfection or non-viral transfection and lipid based transfection, all of which may involve the use of gene therapy vectors. Direct injection has been used to introduce naked DNA into cells in vivo (see e.g., Acsadi et al. (1991) Nature 332:815-818; Wolff et al. (1990) Science 247:1465-1468). A delivery apparatus (e.g., a Eugene gun") for injecting DNA into cells in vivo may be used. Such an apparatus may be commercially available (e. g., from BioRad).
Naked DNA may also be introduced into cells by complexing the 5 DNA to a can on, such as polylysine, which is coupled to a ligand for a cell-surface receptor (see for example Wu, G.
and Wu, C. H. (1988) J. Biol. Chem. 263:14621; Wilson e1. al.
(1992) J. Biol. Chem. 267:963-967; and U.S. Pat. No.
5,166,320). Binding of the DNA-ligand complex to the 10 receptor may facilitate uptake of the DNA by receptor-mediated endocytosis. A DNA-ligand complex linked to adenovirus capsids which disrupt endosomes, thereby releasing material into the cytoplasm, may be used to avoid degradation of the complex by intracellular lysosomes (see for example 15 Curiel e1 al. (1991) Proc. Natl. Acad. Sci. USA 88:8850;
Cristiano et al. (1993) Proc. Natl. Acad. Sci. USA 90:2122-2126) .
Defective retroviruses are well characterized for use as gene therapy vectors (for a review see Miller, A. D.
20 (1990) Blood 76:271). Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard 25 laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines include .psi.Crip, .psi.Cre, .psi.2 and .psi.Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464; Wilson et al. (1988) Proc. Natl. Acad. Sci. USA 85:3014-3018; Armentano et al.
(1990) Proc. Natl. Acad. Sci. USA 87:6141-6145; Huber et al.
(1991) Proc. Natl. Acad. Sci. USA 88:8039-8043; Ferry et al.
(1991) Proc. Natl. Acad. Sci. USA 88:8377-8381; Chowdhury et al. (1991) Science 254:1802-1805; van Beusechem et al. (1992) Proc. Natl. Acad. Sci. USA 89:7640-7644; Kay et al. (1992) Human Gene Therapy 3:641-647; Dai et al. (1992) Proc. Natl.
Acad. Sci. USA 89:10892-10895; Hwu et al. (1993) J. Immunol.
150:4104-4115; U.S. Pat. No. 4,868,116; U.S. Pat. No.
4,980,286; PCT Application WO 89/07136; PCT Application WO
89/02468; PCT Application WO 89/05345; and PCT Application WO
92/07573).
Adeno-associated virus (AAV) may be used as a gene therapy vector for delivery of DNA for gene therapy purposes.
AAV is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al. Curr. Topics in Micro. and Immunol.
(1992) 158:97-129). AAV may be used to integrate DNA into non-dividing cells (see for example Flotte et al. (1992) Am.
J. Respir. Cell. Mol. Biol. 7:349-356; Samulski et al. (1989) J. Virol. 63:3822-3828; and McLaughlin et al. (1989) J.
Virol. 62:1963-1973). An AAV vector such as that described in Tratschin et al. (1985) Mol. Cell. Biol. 5:3251-3260 may be used to introduce DNA into cells (see for example Hermonat et al. (1984) Proc. Natl. Acad. Sci. USA 81:6466-6470; Tratschin et al. (1985) Mol. Cell. Biol. 4:2072-2081; Wondisford et al.
(1988) Mol. Endocrinol. 2:32-39; Tratschin et al. (1984) J.
Virol. 51:611-619; and Flotte et al. (1993) J. Biol. Chem.
268:3781-3790). Lentiviral gene therapy vectors may also be adapted for use in the invention.
General methods for gene therapy are known in the art. See for example, U.S. Pat. No. 5,399,346 by Anderson et al. A biocompatible capsule for delivering genetic material is described in PCT Publication WO 95/05452 by Baetge et al.
Methods of gene transfer into hematopoietic cells have also previously been reported (see Clapp, D. W., et al., Blood 78:
1132-1139 (1991) Anderson, Science 288:627-9 (2000): and, Cavazzana-Calvo et al., Science 288:669-72 (2000)).
In another embodiment, a vector encoding a bacteriocin derived from a lactic acid bacteria can be introduced into a cell in vitro. Such cell may, in an embodiment, produce and/or secrete the bacteriocin. This genetically modified cell can then be inserted into a host having a cancer. In an embodiment, the genetically modified cell is inserted into the host in proximity to the tumor or the metastases. In yet another embodiment, the inserted genetically modified cell produces or secretes the bacteriocin into the host. In another embodiment, the genetically modified cell is autologous or non-autologous to the host.
Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. In the claims, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to". The following examples are illustrative of various aspects of the invention, and do not limit the broad aspects of the invention as disclosed herein.
EXAMPII~ES
Antimicrobial peptides, such as bacteriocins, possess cationic and amphipathic properties which allow interactions with the membrane of living cells. Many such cationic peptides could have interesting and various biomedical and health applications (Marshall and Arenas, 2003). Potential uses may be as components of cosmetics (Reisch, 2002), as antibiotics (Hancock and Lehrer, 1998), as analgesics (Crescenzi et al., 2000), and as agents to prevent oral mucositis (Chen et al., 2000) or to fight herpes viruses (Wachsman et al., 1999; Wachsman et al., 2003). Some bacteriocins have been reported to also possess antitumor activity (Winder et al., 1998).
Bacteriocins produced by lactic acid bacteria (LAB) are antimicrobial peptides, and they have recently gained interest for their potential as food preservatives, as well as for medical applications (Nes and Holo, 2000). An example is nisin, which is produced by Lactococcus lactis. This natural inhibitor is well known (Ross et al., 1999) and has been used for a long time as a food preservative (Breukink and Kruijff, 1999). Most recently, it has been considered to be useful for the treatment of gastric Helicobacter and/or ulcerous infections (Guder et al., 2000; Hancock, 1997; Ross et al., 1999; Uteng et al., 2002). Other LAB bacteriocins, belonging to the class IIa (pediocin, lactacine, etc.), are very interesting and they are starting to be considered seriously as a group of antimicrobial compounds worth investigating for future medical use (Nes and Holo, 2000).
Pediocin PA-l, one of the known class IIa bacteriocins, is produced by Pediococcus acidilactici PAC 1.0 and is strongly active against Listeria monocytogenes (Bhunia et al., 1988). The primary structure of pediocin PA-1 consists of 44 amino acids and its theoretical molecular weight is 4624 Da (refer to figure 2, SEQ ID NO: 2), in the presence of its two disulfide bonds, known to be very important for its biological activity (Gaussier, 2003; Henderson et al., 1992;
Rodriguez et al., 2002). Advances in the understanding of pediocin PA-1 structure, mode of action and biosynthesis will greatly increase the potential usefulness of pediocin PA-1 in different fields. Recent studies revealed that production of recombinant pediocin PA-1 in the methylotrophic yeast Pichia pastoris led to unexpected inhibition of its biological activity (Example 2). This astonishing phenomenon raised several questions and, especially, it has demonstrated a particular feature of the function and/or structure of pediocin PA-l, i.e., that pediocin PA-1 may possess a somewhat "collagen-like" nature.
Recently, the role of collagen-derived proteolytic fragments in angiogenesis was investigated (Marneros and Olsen, 2001). Antitumoral effects have been demonstrated for cecropin, melittin and magainine (Baker et al., 1993; Jaynes et al., 1989; Moore et al., 1994; Ohsaki et al., 1992;
Sharma, 1992). In the case of melittin, the hyperactivation of phospholipase A2 in ras-transformed cells was in part responsible for the antitumoral activity (Winder et al., 1998).
In the studies described herein, the potential of growth inhibition of pediocin PA-1 on the A-549 human lung carcinoma cell line and the DLD-1 human colon adenocarcinoma cell line was evaluated.
Example I - Production of native/natural pediocin PA-I
Pediococcus acidilactici strain PAC 1.0 (Quest International, Sarasota, Fla.) was cultivated in a 20 L
fermentor (Chemap, Switzerland) equipped with pH and p02 electrodes (Ingold), a foam sensor, and a mechanical foam breaker. It was grown in 16 L of Lactobacilli MRS broth (Oxoid); a 1% (v/v) inoculum was used and incubation was done at 37°C for 18 h at an agitation rate of 200 rpm. No 5 additional aeration was provided and no chemical antifoam was added during cultivation.
The cells were separated from the broth by centrifugation (50008, 15 min, 20°C). The supernatant fluid was concentrated 13-fold using a 0.5m2 1 kDa (cut-off) 10 regenerated cellulose membrane k(PCACTM membrane, Millipore), then, diafiltered against 5mM ammonium acetate buffer, pH°5.0, using a PelliconTM system (Millipore) with a Masterflex peristaltic pump at a recirculation rate of 200 ml/min. The process was performed at room temperature.
15 Ion exchange chromatography (IEX). Pediocin PA-1 purification was achieved using a modification of the procedure described by Gaussier et al. (2002). Pediocin PA-1 from the concentrated supernatant fluid (1200 ml) was captured using a SP-Sepharose Fast FlowTM can on exchange 20 column (Amersham). The C26/40 column was packed with 80 ml of resin and connected to a FPLC chromatography system coupled to an UVl-detector (Amersham; reading at OD280 nm). The column was equilibrated with 10 CV (CV = column volume) of 5mM ammonium acetate buffer, pH 5.0 (Buffer A). The pediocin 25 PA-1 solution was applied to the column at a rate of 226 cm/h, then, the column was washed successively with Buffer A and Buffer A containing 0.25M NaCl. Pediocin PA-1 was eluted from the column with Buffer A containing 0.5M
NaCl.
30 Hydrophobic interaction chromatography (HIC) Screening of chromatography media. Several HIC media with varying hydrophobicity were tested, namely: Butyl-SepharoseTM, Amersham; Butyl-650M, Tosohaas; Octyl-SepharoseTM CL 4B, Amersham; Phenyl-SepharoseTM, Amersham; Phenyl-650M, Tosohaas.
Media (1 ml) were equilibrated with 5mM ammonium acetate buffer, pH 5.0 (Buffer A) containing 0.5M NaCl, mixed with 5 ml of the SP-SepharoseTM FF eluate (previous step) and the mixtures were incubated for 1 h at room temperature. A first wash with Buffer A containing 0.5M NaCl was performed followed by elution with Buffer A (5mM ammonium acetate buffer, pH 5.0) and then, by a second elution with Buffer A
containing 500 (v/v) acetonitrile. Biorad Econo-ColumnsTM were used for the screening work and elution was performed by gravity. Eluate fractions were analyzed for pediocin PA-1's biological activity by an agar spot test on a MRS agar medium (Rodriguez et al, 2002).
Refinement of the HIC method. The active fractions collected from the SP-SepharoseTM column were pooled and applied to an Octyl Sepharose~~~M CL-4B hydrophobic interaction column (HR5/5, 1 ml CV, Amer~;ham) using the FPLC system. The column was equilibrated with Buffer A containing 0.5M NaCl.
The pediocin solution was applied to the HIC column at the rate of 306 cm/h, the column was washed with the same equilibration buffer, followed by a second wash with Buffer A. Pediocin PA-1 was eluted with Buffer A containing 500 (v/v) acetonitrile. All of the initial developmental work was performed using 1 ml CV HR5/5 HIC columns (Amersham). Later, a 40 ml CV XK26 column (Amersham) was used to generate more pediocin PA-1 material. The active fractions were pooled and concentrated (13-fold) using a 350 ml Stir Cell system (Amicon) and a lkDa (cut-off) regenerated cellulose membrane (YMl, DiafloTM ultrafiltration membrane, Amicon) ending with diafiltration against water (HPLC grade). The retentate was lyophilized (Flexi-dryTM, FTS Systems Inc.) and the material was stored at 4°C under a NZ atmosphere.
Example 2 - Production of recombinant pediocin PA-I in Pichia pastoris Strains, plasmids and culture conditions.
Escherichia coli TOP10 was grown in Luria-Bertani (LB) broth (lo tryptone, 1o NaCl, 0.50 yeast extract, pH 7.0). E.coli transformants were grown in L,ow Salt Luria-Bertani (LSLB) medium, supplemented with zeocin (25~g/ml) overnight at 37°C.
Pediococcus acidilactici PAC1.0 and Pediococcus pentosaceus FBB63 were grown in Lactobacilli MRS broth (Oxoid) for 18h at 37°C. Yeast strains were cultured in YPD (lo yeast extract, 2% peptone, 2o glucose) medium, whereas yeast transformants were grown in baffled shake flasks under selective conditions in buffered glycerol-complex medium (BMGY: to yeast extract, 2o peptone, 100mM potassium phosphate, pH 6.0, 1.340 yeast nitrogen base without amino acids, 4X10-So biotin, to glycerol) until cultures reached an OD6oonm between 2 and 6.
The cultures were harvested by centrifugation (5000 g, 15 min, 4°C) and the cells were grown for another 3 days at 30°C in buffered methanol complex medium (BMMY: to yeast extract, 2% peptone, 100mM potassium phosphate, pH 6.0, 1.340 yeast nitrogen base without amino acids, 4X10-50 biotin, to methanol) for the induction of pediocin PA-1 gene expression.
Samples were taken at different times (0, 6, 12, 24, 48, 72°h) for analysis. Experiments were performed according to the guidelines supplied by the EasySelectTM Pichia Expression Kit (Invitrogen Corporation).
Cloning of pedA and plasmid construction. A DNA
fragment encoding the mature domain of pedi.ocin PA-1 was obtained by polymerase chain reaction (PCR) amplification of pSRQl1 DNA isolated from Pediococcus acidilactici PAC1.0 using the QIAprepTM Spin Miniprep Kit protocol (QIAgen) and with an alkaline lysis procedure (2001 of a cold solution containing 50mM glucose, lOmm EDTA, 25mM Tris pH 8.0 and 4 mg/ml of lysozyme, from Sigma, were added after step 3).
The sequence of the 5' primer used for amplification (5'-AAA
AAA CTC GAG AAA AGA GAG GTC GAA GCT AAA TAC TAC GGT AAT GGG-3' [SEQ ID NO: 3]) begins with 6xA nucleotide clamp, followed by a XhoI restriction enzyme site (CTCGAC), the Kex2 signal cleavage sequence (AAAAGAGAGGTCGAAGCT [SEQ ID N0: 4]) and ends with a 18 nucleotide sequence complementary to the first nucleotides of the pedA gene encoding for the mature peptide form. The 3' primer (5'-AAA AAA GTC GAC TTA TCA CTA GCA TTT
ATG ATT ACC TTG ATG TC-3'[SEQ ID NO: 5]) contains 6xA
nucleotide clamp, followed by an AccI restriction enzyme site (GTCGAC), and the stop codons to end with a 23 nucleotide sequence complementary to the final eight codons of the pedA
gene. PCR amplification was performed with 40U of rTaq DNA
polymerase (Amersham) per ml, 1.35 pg of pSRQll template per ml, 1.25mM of each nucleoside triphosphate, and 2 ~g of each primer per ml. PCR was performed to amplify DNA with a hot start at 96°C for 1 min and then 30-cycles of amplification (96°C, 30s for strand denaturation, 55°C, 30s for primer annealing, and 72°C, 60s for primer extension) followed by a final extension at 72°C for 2 min. The PCR product was purified using the QIAquickTM PCR Purification Kit Protocol (QIAgen) and digested with XhoI and AccI restriction endonucleases (Amersham and New England Biolabs, respectively). The resulting fragment was purified by agarose gel electrophoresis using the QIAexTM II agarose gel extraction kit (QIAgen) and ligated with T4 DNA Ligase (New England Biolabs) between the XhoI and AccI restriction sites within the pPICZaA vector. pPICZaA was pre-digested with the same enzymes. Ligation mixtures were transformed into competent E.coli TOP10 cells (TOPO TA Cloning, Version K, Invitrogen). In vitro DNA manipulation (digestion, ligation) for cloning in E. coli were performed as described by Sambrook et al. (1989). The pPICZaA-pedA expression plasmid, isolated using the QIAgen Plasmid Maxi Protocol (QIAgen), was identified by restriction enzyme digestion with XhoI/AccI and BamHI/SacI (New England Biolabs). The pedA gene region was confirmed by double-stranded DNA sequencing with AmpliTaq DNA
polymerase (ABI PRISMTM Dye Terminator Cycle Sequencing Ready Reaction Kit) using an ABI 377XL DNA Sequencer (Applied Biosystems). For PCR sequencing reactions, 5' and 3' AOXl primers were used to confirm that the pedA gene was in frame with the C-terminal of the a-factor (EasySelectTM Pichia Expression Kit, Invitrogen Corporation). PCR reactions were purified on a Centri-SepTM column (Applied Biosystems) prior to performing sequence analysis. pPICZaA (10 fig) and pPICZaA-pedA (10 fig) vectors were linearized with 40U of SacI
restriction endonuclease (Amersham) following the recommendations given by the EasySelectTM Pichia Expression Kit (Invitrogen Corporation). Linearized vectors were electroporated into P. pastoris. Electro-competent cells (80 ~l) were mixed with DNA solution (10 fig) in a 0.2 cm gap cuvette chilled on ice. Electroporation was carried out using a Gene PulserTM (Bio-Rad) with the following parameters:
1.5 kV, 40052, 25 ~F to a final field strength of 7.5 kV cm-1.
After cells had been pulsed, 1 ml of ice-cold sterile 1M
sorbitol was immediately added to the cuvette, the cell suspension was transferred into a test tube, and the mixture incubated at 30°C for 1h30. Transformed clones were selected on Yeast Extract Peptone Dextrose Sorbitol medium (YPDS: 1%
yeast extract, 2o peptone, 2o dextrose, 1M sorbitol, 2% agar) containing zeocin (100 ~g/ml). Transformants were also tested on both Minimal Dextrose Medium, with and without histidine, (1.340 yeast nitrogen base without amino acids, 4X10-5o biotin, 2o dextrose, with and without 0.0040 histidine, 1.50 agar) and Minimal Methanol Medium, with and without histidine, (1.340 yeast nitrogen base without amino acids, 4X10-5o biotin, 2o methanol, with and without 0.004%
5 histidine, 1.50 agar) plates to confirm the Mut+ phenotype of the X-33 and GS115 strains.
Detection of activity of pediocin PA-1 by agar spot test. All transformants were grown in shake flasks as mentioned before and tested by agar spot test on MRS medium 10 (Parrot et al., 1990) for detection of biological activity. A
MRS plate (1.50 (w/v) agar, 20 ml) was covered with 5 ml of soft agar (0.80 (w/v) agar) containing an overnight MRS-grown culture of the indicator strain P. pentosaceus (adjusted to an OD6oonm of 0.1, Beckman DU 640 Spectrophotometer).
15 Supernatant fluid samples were filtered using a 0.22 ~m membrane (Syringe Driven Filter Unit, Millex-HV, 4 mm) and 5 ~l of each sample was added to the surface of the soft agar. The plates were incubated for 18h at 37°C and examined for the presence of clear zones indicating growth inhibition.
20 The recombinant Pichia was grown in baffled shake flasks in BMGY medium until glycerol was exhausted and, then, in BMMY medium with methanol (0.50 (v/v)) for 3 days. The cultures were harvested by centrifugation (5000g, 15 min, 4°C) and the supernatant fluids analyzed. Expression levels 25 were monitored by quantitative ELISA testing. A pediocin concentration of 74 ~g/ml was achieved in Pichia comparison with 6 ~g/ml for the natural producing strain of P.
acidilactici (Example 1). However, biological activity against P. pentosaceus was not detected in the supernatant 30 fluids of the P. pastoris cultures tested several times over a 72 h induction period (0, 6, 12, 24, 48 and 72h).
Example 3 - Materials and Methods - Anticancer activity of natural and recombinant pediocin PA-1 Pediocin PA-1. Both highly purified pediocin PA-1 (Example 1), obtained from the naturally producing Pediococcus acidilactici PAC 1.0 strain (Quest International, Sarasota, Fla.), and semi-purified recombinant pediocin PA-1 (Example 2), produced by Pichia pastoris (KMH71, MutS
phenotype, Invitrogen) were tested in this study. Production and purification was done as described earlier for natural pediocin PA-1 (Example 1) and for the recombinant pediocin PA-1 (Example 2).
Cell culture. The human lung carcinoma cell line A-549 and the human colon adenc>carcinoma cell line DLD-1 were obtained from the American Type Culture Collection (ATCC).
I5 Both cell lines were cultured in minimum essential medium containing Earle's salts and L-glutamine (Mediatech Cellgro, VA), to which were added loo fetal bovine serum (Hyclone), vitamins (1X), penicillin (100 I.U./ml) and streptomycin (100 ~g/ml), essential amino acids (1X) and sodium pyruvate (1X) (Mediatech Cellgro, VA). Cells were kept at 37°C in a humidified environment containing 5o CO2.
Anticancer activity assay. Exponentially growing cells were plated in 96-well microplates (Costar, Corning inc.) at a density of 5 x 103 cells per well in 100 ~l of culture medium and were allowed to adhere for 16 h before treatment. Increasing concentrations of both natural and recombinant pediocin PA-1 in culture medium (minimum essential medium, described previously) were then added (100 ~l per well). The cells were incubated for 48 h in the presence or absence of pediocin PA-1. The cell growth was assessed using the resazurin reduction test (0'Brien et al., 2000). Fluorescence was measured on an automated 96-well Fluoroskan Ascent F1TM plate reader (Labsystems) using excitation and emission wavelengths of 350 nm and 590 nm, respectively. Anticancer activity was expressed as the concentration of natural or recombinant pediocin PA-1 inhibiting cell growth by SOo (ICSO). The experiment was repeated and produced very similar results.
Example 4 - Results - Anticancer activity of natural and recombinant pediocin PA-I
Anticancer drug discovery using human tumor cell lines has attracted increasing interest since the mid-1980s (Baguley and Marshall, 2004). Some antimicrobial peptides are known to exhibit antitumor activity in tumor-derived cell lines (melittin, cecropin, magainin) (Winder et al., 1998).
The potential anticancer activity of pediocion PA-1 was evaluated herein. Both natural pediocin PA-1 and recombinant pediocin PA-l, obtained in an inactive form from the yeast Pichia pastoris, were assayed for their anticancer activity on two carcinoma cell lines using the resazurin reduction test (0'Brien et al., 2000). The two cell lines tested were a human lung carcinoma cell line (A-549) and a human colon adenocarcinoma cell line (DLD-1). Natural, highly purified pediocin PA-1 showed a antiproliferative effect on both cell lines (two separate experiments) while no growth inhibition was observed for recombinant, semi-purified pediocin PA-1 (Table 1 - below). Natural pediocin PA-1 showed very similar ICSO (~M) values for both human cell lines, which were 1.66 ~M
for lung tumoral cells and 1.61 ~M for colon tumoral cells.
Such values are indicative of significant clinical potential and have also been reported for other therapeutic agents of medicinal importance (DNA-reactive compounds, antimetabolites, mitotic poisons, topoisomerase poisons)(Luber and Hardy, 2001).
TABLE 1: Anticancer activity (ICso) of highly purified natural pediocin PA-1*
Human cell line Pediocin PA-1 ICso (~g/ml) A-549a 7.66 ~ 0.69 (1.66 ~ 0.15 uM) DLD-1° 7.43 ~ 0.45 (1.61 ~ 0.10 uM) * Recombinant pediocin PA-1 produced by P. pastoris showed no anticancer activity under the same conditions.
Human lung carcinoma cell line.
Human colon adenocarcinoma cell line.
In the past, some authors have demonstrated that partially purified bacteriocins (PPBs) (Farkas-Himsley, 1988;
Hill and Farkas-Himsley, 1991.) obtained from certain non-lactic acid bacteria (colicins from E. coli, vibriocins from V. cholera and pyocins from P. aeruginosa) (Farkas-Himsley et al., 1975; Farkas-Himsley and Cheung, 1976; Farkas-Himsley and Musclow, 1980) under specific growth conditions (Farkas-Himsley and Yu, 1985), contained materials which were active on various malignant cells, both in vitro (Farkas-Himsley, 1980; Farkas-Himsley et al., 1975; Farkas-Himsley and Cheung, 1976) and in vivo (Hill and Farkas-Himsley, 1991). The PPBs demonstrated selective killing characteristic, differentiating malignant from normal cells (Farkas-Himsley, 1980; Musclow et al., 1987). These authors also noted that the malignant cells which interacted with PPBs contained less DNA than the control cells not treated with PPBs (Farkas-Himsley and Yu, 1985). It was also shown that PPBs interacted with the cell surface, possibly via transferrin receptors (Farkas-Himsley and Musclow, 1986). And finally, they reported that PPBs most likely belonged to the group of proteins that interact with external cell surface receptors and are able to signal the activation of endonucleolytic processes. This supported the hypothesis that PPBs cause programmed cell death by apoptosis (Farkas-Himsley et al., 1992) .
However, the partially purified bacteriocins studied were rather ~~crude" preparations and it possible that contaminating materials (e.g. endotoxins) may have been the cause of variability in the results, primarily for the in vivo experiments. It was recognized that much better purification of the bacteriocins would be required before establishing more definitive conclusions (Fumorola, 1978;
Fumorola et al., 1977). In the case of the highly purified pediocin PA-1 preparation tested herein, the results obtained are noticeably much more valuable due to the quality and the purity of the pediocin PA-1 preparation used.
Further, some bacteriocins can be toxic to mammalian cells (Murinda et al., 2003). Thus, some bacteriocins often intended for use as biopreservatives need to be evaluated for toxicity to mammalian cells.
In contrast, LAB and products derived therefrom are generally considered safe. Indeed, studies carried out with nisin A and pediocin PA-1/AcH have indicated that both bacteriocins are nontoxic to laboratory animals and humans when used at the recommended levels. As such, the uses of LAB-derived bacteriocins described herein provide the advantage of being both safe and having anticancer activity.
In the present study, natural pediocin (e. g.
produced by Pediococcus sp.) showed anticancer activity whereas the recombinant pediocin produced by Pichia sp.
showed no activity. The latter observation is consistent with previous results showing the absence of biological activity for recombinant pediocin PA-1 (Example 2).
Example 4 - Production of recombinant pediocin PA-1 in 5 Escherichia coli Strains, plasmids and culture conditions. The sources and relevant genotypes of bacterial strains, as well as the plasmids used in this study are listed in Table I.
Escherichia coli DHSa, used for standard cloning procedures, 10 and the Origami (DE3) cell line, used for gene expression experiments, were grown in Luria-Bertani (LB) broth (1.0o tryptone, 1.0% NaCl, 0.5o yeast extract, pH 7.0).
Transformants of E.coli were selected onto LB medium supplemented with ampicillin (60 ~g/ml). Pediococcus 15 acidilactici PAC 1.0, the producing strain of pediocin PA-1, and Pediococcus pentosaceus FBB63, used as indicator strain, were grown in Lactobacilli MRS broth (Oxoid) for 18h at 37°C.
Cloning of pedA and plasmid construction. In vitro DNA manipulations (digestion, ligation, transformation) for 20 cloning in E. coli were performed as described by Sambrook et al. (1989). A DNA fragment encoding the mature domain of pediocin PA-1 was obtained by polymerase chain reaction (PCR) amplification of pSRQll DNA isolated fram Pediococcus acidilactici PAC 1.0 using the QIAprepTM Spin Miniprep Kit 25 protocol (QIAgen) with an alkaline lysis procedure (2001 of a cold solution containing 50mM glucose, lOmM EDTA, 25mM Tris pH 8.0 and 4mg/ml of lysozyme (Sigma) were added after step 3). The sequence of the 5' primer used for amplification (5'-AAC CCC AGA TCT CGA CGA CGA CAA GAA ATA CTA CGG TAA TGG G-3' 30 [SEQ ID NO: 6]) begins with AACCCC nucleotides clamp followed by a BglII restriction enzyme site (AGATCT), the enterokinase cleavage sequence (CGACGACGACAAGAA [SEQ ID N0: 7]) and ends with a 18 nucleotide sequence complementary to the first nucleotides of the pedA gene encoding for the mature peptide form. The 3' primer (5'-CCC GGG CTC GAG CTA TTA TCA GCA TTT
ATG ATT ACC TTG ATG TCC A-3' [SEQ ID NO: 8]) contains CCCGGG
nucleotides clamp, followed by an XhoI restriction enzyme site (CTCGAG), the stop colons and ends with a 25 nucleotide sequence complementary to the final eight colons of the pedA
gene. PCR amplification was performed using 40U of Deep VentTM
(exo-) DNA polymerase (New Englands Biolabs) per ml, 1.35 pg of pSRQll template per ml, 1.25mM of each nucleoside triphosphate, and 2 ~g of each primer per ml. PCR was performed to amplify DNA with a hot start at 96°C for 1 min and, then, 30 cycles of amplification (96°C, 30s for strand denaturation; 60°C, 30s, for primer annealing and 72°C, 60s, for primer extension) followed by a final extension at 72°C
for 1 min. The PCR product was purified using the QIAquickTM
PCR Purification Kit Protocol (QIAgen) and digested with BglII and XhoI restriction endonucleases (New England Biolabs). The resulting fragment was purified by agarose gel electrophoresis using the QIAex IITM agarose gel extraction kit (QIAgen) and ligated with T4 DNA Ligase (New England Biolabs) between the BglII and XhoI restriction sites within the pET32b vector. pET32b was pre-digested with the same enzymes. Ligation mixtures were transformed into competent E.coli DHSa cells employing the CaCl2 approach. The pET32b-pedA expression plasmid, isolated using the QIAprepTM Spin Miniprep Kit protocol (QIAgen), was identified by restriction enzyme digestion with XbaI/XhvI (New England Biolabs).
Vectors (pET32b and pET32b-pedA) were transferred into E.coli Origami (DE3) cells. Transformants were selected on Luria Bertani (LB) medium containing ampicillin (60 ~g/ml). The pET32b vector and the pET32b-pedA expression plasmid were isolated using the QIAprepTM Spin Miniprep Kit protocol (QIAgen). The pedA gene region was confirmed by double-stranded DNA sequencing with AmpliTaqTM DNA polymerase (ABI
PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit) using an ABI 3777XL DNA Sequencer (Applied Biosystems). For PCR sequencing, the sequence of the 5' primer used for amplification was (5'-TTC CTT TCG GGC TTT GTT AGC AGC-3' [SEQ
ID N0: 9]) and the sequence of the 3' primer was (5'-TAA ATT
CGA ACG CCA GCA CAT GGA-3' [SEQ ID N0: 10]). These primers corresponded to nucleotide sequences complementary to the upstream and downstream regions of the pedA gene to confirm that its position was in frame with the thioredoxin gene. PCR
reaction products were purified using Centri-SepTM columns (Applied Biosystems) prior to sequencing.
Expression of pediocin PA-1 in E.coli.
Transformants (clone Bl) of E.coli Origami (DE3), stored in 15% glycerol kept at -80°C (0.7 ml), were grown in 2 separate shake flasks of 2L, each with 500 ml of LB medium supplemented with ampicillin ;100 ~g/ml) until the culture reached an OD600 of 0.6-0.8 (approximately 7h). Protein expression was induced by addition of isopropyl ~-D-thiogalactoside (IPTG, Sigma) to a final concentration of 20 ~M. The culture was harvested four hours after induction by centrifugation (30008, 25 min, 4°C). The cell pellets were stored frozen at -20°C prior t.o analysis.
Preparation of cleared cell lysates. Cell lysates were prepared using frozen cells from one liter of culture.
Cells were resuspended in 100 ml of 50 mM sodium phosphate buffer, pH 8.0, containing 300 mM NaCl. The mixture was homogenized using a high-pressure homogenizer (Microfluidics International Corporation, Newton, MA) to disrupt the cells.
Cell breakage, done on ice, was initially performed using a resting pressure of 60psi (0.4MPa) corresponding to an internal pressure of 17000psi (117MPa) and it was repeated 3 times. The resulting cell lysate was centrifuged at 140008 for 30 min at 4°C to remove the insoluble fraction. Cleared cell lysate was filtered using a 0.45~m, low protein binding membrane (Cellulose acetate, Corning) and stored at -20°C
until needed.
Affinity purification of fusion protein under native conditions. Fusion protein (Trx-pedA) present in the cleared cell lysate was captured using a Ni-NTA agarose resin (QIAgen). The VL11 X 250 Amicon column was packed with lOml of resin and connected to a GradiFracTM Chromatography system integrated with an UV1-detector (UV lamp, OD280 nm, Amersham). The column was equilibrated with 10 CV (column volume) of 50mM sodium phosphate buffer, 300 mM NaCl, pH 8.0 (Buffer A). Cleared cell lysate solution (100 ml) was applied to the column at a rate of 30b cm/h, then, the column washed with Buffer A. The fusion protein was eluted with Buffer A
containing 250mM imidazole (ICN Biomedicals, Inc.).
Concentration and diafiltration. Fractions containing Trx-pedA were pooled and concentrated in a 350m1 Stir Cell system (Amicon) using a 3kDa (cut-off) regenerated cellulose membrane (YM3, Diaflo ultrafiltration membrane, Amicon) and diafiltered against 20mM Tris-HCl, 50mM NaCl, 2mM
CaCl2 buffer, pH 7.4 (cleavage buffer).
Site-specific cleavage of Trx-pedA using recombinant enterokinase. The retentate (26 ml) obtained after the concentration step was treated with 80U of recombinant enterokinase (rek, Novagen) overnight at room temperature under gentle rotational agitation (Adams Nutator). The reaction mixture was centrifuged (5 min, 18118 at 20°C) and supplemented with NaCl to reach a concentration of 0.5M. The pH was adjusted with HC1 (0.1N) to 5.0 prior to hydrophobic interaction chromatography (HIC).
Hydrophobic interaction chromatography. The retentate after recombinant enterokinase treatment, which contained biologically active pediocin PA-l, was applied to an Octyl Sepharose CL-4B hydrophobic interaction column (HR5/5, 1 ml CV, Amersham) using a GradiFrac system as mentioned above (Example 1). The column was equilibrated with 5 mM ammonium acetate buffer, pH 5.0, (Buffer B) containing 0.5 M NaCl. The retentate was applied to the column at 306 cm/h, washed with the same buffer (Buffer B + 0.5 M NaCl) followed by another wash with Buffer B. Pediocin PA-1 was eluted with Buffer B containing 50% (v/v) acetonitrile. After removal of the acetonitrile by evaporation (Rotavapor, Buchi), the preparation was loaded onto a semi-preparative reversed-phase HPLC column.
Semi-preparative HPLC purification. The active recombinant pediocin PA-1 fraction eluated from the Octyl-Sepharose column was loaded onto a C18 reversed-phase column (Semi-prep column CSC-Inertsil 150A/ODS2, 5 um, 25 x l.Ocm) and purified by high-pressure liquid chromatography (Waters Millennium32, Waters Scientific, Mississauga, Ontario, Canada). The system was equipped with a Waters 996 Photo Diode Array detector, a Waters 600E solvent delivery pump, a Waters 717 autosampler, and a Waters temperature control module (TCM). A method incorporating a 10 minute non-linear gradient (curve profile number 5) going from 24% (v/v) acetonitrile in 5 mM HCl to 600 (v/v) acetonitrile in 5 mM
HC1 was utilized. The sample was eluted at a flow rate of 3 ml/min with a column temperature of 39°C. The natural (used as standard) and recombinant pediocin PA-1 peak appeared at a retention time of 6 min, corresponding to an acetonitrile concentration of 510 (v/v). Active fractions were pooled and concentrated with a 50 ml Stir Cell system (Amicon) using a 1 kDa (cut-off) regenerated cellulose membrane (YM1, Diaflo ultrafiltration membrane, Amicon) and diafiltered against water (HPLC grade). The retentate was freeze-dried (Flexi-dry, FTS Systems Inc.) and kept at 4°C under a NZ atmosphere.
Detection of pedioci_n PA-1. Purification was 5 followed using a non-competitive indirect ELISA method (Martinez et al. 2000). Microtiter plate wells (Maxisorp, Nunc) were coated with 100 ~l samples diluted in CB (CB =
Coating Buffer: 0.1 M sodium carbonate-bicarbonate buffer, pH
9.6). The plates were incubated overnight at 4°C, blocked for 10 1h at 37°C with 300 ~1 of to (w/v) ovalbumin (Sigma, grade III) in PBS (phosphate-buffered saline O.OlM, pH 7.4) and washed with 0.050 Tween 20 in PBS. Then, 50 ~l of polyclonal antibodies against pediocin PA-1 (antiserum provided by Professor P. E. Hernandez; Martinez et al. 1998) diluted 1000 15 times in PBS were added and the plates incubated for 1h at 37°C. Goat anti-rabbit IgG-HRP (Horseradish Peroxidase) (Biorad) diluted 500 times in ovalbumin solution (lo (w/v) in PBS; blocking solution) was added and the complex was revealed by adding 100 ~l of ABTS (2,2'-azino-bis(3-20 ethylbenzthiazoline-6-sulphonic acid) substrate (Sigma).
Absorbance was read at 405 nm using a SPECTRAFluor Plus Spectrophotometer (TECAN Austria Gmbh, Grodig, Austria).
Activity test of pediocin PA-1. Samples were analyzed by agar spot test on MRS agar medium (Parrot et al.
25 1990). A MRS 1.5o agar plate (20 ml) was covered with 5m1 of soft agar (0.8% (w/v) agar) containing a MRS-grown overnight culture of the indicator strain Pediococcus pentosaceus (adjusted to an optical density of 0.1 at 600 nm, Beckman DU
640 Spectrophotometer). Samples were filtered using a 0.22 ~m 30 membrane (Syringe Driven Filter Unit, Millex-HV, 4mm) prior to addition of 5 ~l onto the surface of the soft agar. The plates were incubated for 18h at 37°C and examined for growth inhibition zones.
Biological activity of the recombinant pediocin PA-1 was also analyzed after Trx-PedA cleavage using the agar spot test method (Parrot et a1.1990). Table 2 shows the dish overlay results. An inhibition zone of growth was observed for section 1 corresponding to the natural pediocin PA-1 standard (Example 1). Biological activity was not detected for the uncleaved Trx-pedA. A very marked inhibition zone was noted for the recombinant ped:iocin PA-1 after cleavage by the enterokinase, which was comparable to that observed with natural pediocin PA-1.
Table 2 - Measurements of natural and recombinant pediocin activity using the dish overlay assay Type of pediocin used Inhibition of growth of Pediococcus pentosaceus Natural ~+++
Recombinant uncleaved Recombinant cleaved I+++
Throughout this application, various references are referred to describe more fully the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.
REFERENCES
Baguley, B. C. and Marshall, E. S. (2004) In vitro modelling of human tumour behaviour in drug discovery programmes.
Eur J Cancer. 40: 794-801.
Baker, M. A., Maloy, W. L., Zasloff, M. and Jacob, L. S.
(1993) Anticancer efficacy of magainin 2 analogue peptides. Cancer Res. 53: 3052-3057.
Bhunia, A. K., Johnson, M. C. et Ray, B. (1988) Purification, characterization and antimicrobial spectrum of a bacteriocin produced by Pediococcus acidilactici. J Appl Bacteriol. 65(4) . 261-268.
Breukink, E. and de Kruijff, B. (1999) The lantibiotic nisin, a special case or not?. Biochim Biophys Acta. 1462: 223 234.
Chen, J., Falla, T. J., Liu, H., Hurst, M. A., Fujii, C. A., Mosca, D. A., Embree, J. R., Loury, D. J., Radel, P. A., Chang, C. C., Gu, L. and Fiddes, J. C. (2000) Development of protegrins for the treatment and prevention of oral mucositis: Structure-activity relationships of synthtic protegrin analogues.
Biopolymers (Peptide Science). 55:88-98.
Crescenzi, O., Guerrini, R., Picone, D., Salvadori, S., Tancredi, T., Temussi, P. A. (2000) Solution structure of novacistatin, a new peptide analgesic. Biopolymers.
53:257-264.
Farkas-Hiinsley, H. (1988) Sensitivity of various malignant cell lines to partially purified bacteriocins: inherent and proliferative dependance. Microbios Lett. 39: 57-66.
Farkas-Himsley, H. (1980) Sensitivity to bacteriocins of murine leukaemias with varying oncogenic potency.
Microbios Lett. 15:89-96.
Farkas-Himsley, H., Cheung, R. (1976) Bacterial proteinaceous products (bacteriocins) as cytotoxic agents of neoplasia. Cancer Res. 36(10): 3561-3567.
Farkas-Himsley, H., Cheung, R. and Tompkins, W. A. F. (1975) Selective antitumor agents: Bacteriocins from Gram-negative bacteria. IRCS Med Sci. 3: 148 Farkas-Himsley, H. and Musclow, C. E. (1980) Bacteriocins in laboratory diagnosis of leukemic cells. IRCS Med Sci. 8:
497-498.
Farkas-Himsley, H. and Musclow, C. E. (1986) Bacteriocin receptors on malignant mammalian cells: Are they transferrin receptors?. Cell Mol Biol. 35(5): 607-617.
Farkas-Himsley, H. and Yu, H. (1985) Purified colicin as cytotoxic agent of neoplasia: Comparative study with crude colicin. Cytobios. 42: 193-207.
Farkas-Himsley, H., Zhang, Y.-S., Yuan, M and Musclow, C. E.
(1992) Partially purified bacteriocin kills malignant cells by apoptosis: programmed cell death. Cell Mol Biol. 38(6): 643-651.
Fumarola, D. (1978) Bacteriocins as cytotoxic agents against tumors: The role of possible contaminants. Boll ist sieroter Milan. pp. 101-102.
Fumarola, D., Bello,P., Palma, R., Miragliotta, G. and Panaro, A. (1977) Bacteri.ocins as cytotoxic agents in experimental neoplasm: considerations on the role of possible contaminants. Giornale di Batteriologica, Virologica ed Immunologia. 70 (1-6): 87-93.
Gaussier, H., Lavoie, M. and Subirade, M. (2003) Conformational changes of- pediocin in an aqueous medium monitored by Fourier transform infrared spectroscopy . A
biological implication. Int J Biol Macromol. 32: 1-9.
Guder, A., Wiedemann, I. and Sahl, H-G. (2000) Posttranslationally modified bacteriocins- The lantibiotics. Biopolymers (Peptide Science). 55: 62-73.
Hancock, R. E. W. (1997). Peptides antibiotics. Lancet 349 :418-422.
Hancock, R. E. W. and Lehrer, R. (1998) Cationic peptides: a new source of antibiotics. Tibtech. 16: 82-88.
Henderson, J. T., Chopko, A. Z. and van Wassenaar, P. D.
(1992) Purification and primary structure of pediocin PA-1 produced by Pediococcus acidilactici PAC 1Ø Arch Biochem Biophys. 295(1): 5-12.
Hill, R. P. and Farkas-Himsley, H. (1991) Further studies of the action of a partially purified bacteriocin against a murine fibrosarcoma. Cancer Research. 51: 1359-1365.
Jaynes, J. M., Julian, G. R., Jeffers, G. W., White, K. L.
and Enright, F. M. (1989) Peptide Res. In vitro cytocidal effect of lytic peptides on several transformed mammalian cell lines. 2: 157-160.
Johnsen, L., Fimlan, G., Eijsink, V, and Nissen-Meyer, J.
(1998) Engineering increased stability in the antimicrobial peptide pediocin PA-1. Appl. Env.
Microbiol. 66(11): 4798-4802.
Luber, A. D. and Hardy, W. D. (2001) Clinical considerations in therapeutic drug monitoring. The body: an AIDS and HIV information resource. HIV Newsline. 7(1):
http://www.thebody.com/hivnews/newsline/feb2001/optimal2 .html.
Marneros, A. G. and Bjorn, O. R. (2001) The role of collagen-derived proteolytic fragments in angiogenis. Matrix Biology. 20: 337-345.
Marshall, S. H. and Arenas, G. (2003) Antimicrobial peptides:
A natural alternative to chemical antibiotics and a potential for applied biotechnology. Elect J Biotechnol.
6(2): 271-284.
Mi-Kyung, S., Woo, S.-G., Jang, J-S., Kim, J.-H., Kim, H.-Y., Hong, S.-G., L~e, B.-W., Park, M.-H. and Chung, K. S.
5 (2003) Immunostimulating and anti-cancer effects of Pediococcus pentosaceus EROM101 isolated from Korea. Kor J Microbiol Biotechnol. 31(4): 355-361.
Miller, K. W., Schamber, R., Osmanagaoglu, O. and Bibek, R.
(2000) Isolation and Characterization of pediocin AcH
10 chimeric protein mutants with altered bactericidal activity. Appl. Env. Res. 64(6): 1997-2005.
Moors, A. J., Devine, D. A. and Bibby, M. C. (1994) Preliminary experimental anticancer activity of cecropins. Peptide Res. 7(5): 265-269.
15 Murinda, S. E., Rashid, K. A. and Roberts, R. F. (2003) In vitro assessment of the cytotoxicity of nisin, pediocin, and selected colicins on Simian Virus 40-transfected human colon and Vero monkey cells with trypan blue staining viability assays. J Food Protect. 66(5): 847-20 853.
Musclow, C. E., Farkas-Himsley, H., Wetzman, S. S. and Herridge (1987) Acute lymphoblastic leukemia of childwood monitored by bacteriocin and flowcytometry.
Eur J Cancer Clin Oncol. 23(4) . 411-418.
25 Nes, I. F. and Holo, H. (2000). Class II antimicrobial peptides from lactc acid bacteria. Biopolymers (Peptide Science). 55: 50-61.
O'Brien, J., Wilson, I., Orton, T. and Pognan, F. (2000) Investigation of the alamar blue (resazurin) fluorescent 30 dye for the assessment of mammalian cell cytotoxicity.
Eur J Biochem. 267: 5421-5426.
Ohsaki, Y., Gazdar, A. F., Chen, H.-C. and Jonhson, B. E.
(1992) Antitumor activity of magainin against human lung cancer cell lines. Cancer Res. 52: 3534-3538.
Reisch, M. S (2002) C & EN Northeast news bureau.
Rodriguez, J. M., Martinet, M. I. and Kok, J. (2002) Pediocin PA-l, a wide-spectrum bacteriocin from lactic acid bacteria. Crit Rev Food Sci. 42(2): 91-121.
Ross, R. P., Galvin, M., McAuliffe, O., Morgan, S. M., Ryan, M. P., Twomey, D. P., Meaney, W. J. and Hill, C. (1999) Developing applications for lactococcal bacteriocins.
Antonie van Leeuwenhoek. 76: 337-346.
Sharma, S. V. (1992) Melittin resistance: a counterselection for ras transformation. Oncogene. 7: 193-201.
Uteng, M., Hauge, H. H., Brondz, I., Nissan-Meyer, J. and Fimland, G. (2002) Rapid two-step procedure for large-scale purification of pediocin-like bacteriocins and other cationic antimicrobial peptides from complex culture medium. Appl Environ Microb. 68(2) . 952-956.
Wachsman, M. B., Farias, M. E., Takeda, E., Sesma, F., de Ruiz Holgado, A. P., de Torres, R. A. and Coto, C. E.
(1999) Antiviral activity of enterocin CRL35 against herpesviruses. Int J Anti.microb Ag. 12: 293-299.
Wachsman, M. B.; Castilla, V.; de Ruiz Holgado, A. P.; de Torres, R. A.; Sesma, F. and Coto, C. E. (2003) Enterocin CRL35 inhibits late stages of HSV-1 and HSV-2 replication in vitro. Antiviral Research. 58: 17-24.
Winder, D., Gunzburg, W. H., Erfle, V. and Salmons, B. (1998) Expression of antimicrobial peptides has an antitumour effect in human cells. Biochemical and Biophysical Research communications. 242: 608-612.
Gaussier, H., H. Morency, M. C. Lavoie, and M. Subirade.
2002. Replacement of triofluoroacetic acid with HCl in the hydrophobic purification steps of pediocin PA-l: a structural effect. Appl. Environ. Microb. 68: 4803-4808.
Parrot, M., Caufield, P. W. and Lavoie, M. C. (1990) Preliminary characterization of four bacteriocins from Streptococcus mutans. Can J Microbiol. 36: 123-130.
Rodriguez, J. M., M. I. Martinet, and J. Kok. 2002. Pediocin PA-l, a wide-spectrum bacteriocin from lactic acid bacteria. Crit. Rev. Food Sci. 42: 91-121.
Claims (116)
1. A method of preventing or treating cancer in an animal, said method comprising administering to said animal an agent selected from the group consisting of:
(a) a bacteriocin derived from a lactic-acid bacteria; and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier.
(a) a bacteriocin derived from a lactic-acid bacteria; and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier.
2. The method of claim 1, wherein said agent is cytotoxic to the cancerous cell of said cancer.
3. The method of claim 1, wherein said agent is administered through a route selected from the group consisting of intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal, intratumoral and topical.
4. The method of claim 1, wherein said agent is said bacteriocin.
5. The method of claim 4, wherein said bacteriocin is substantially pure.
6. The method of claim 1, wherein said bacteriocin is a recombinant bacteriocin.
7. The method of claim 6, wherein said recombinant bacteriocin is produced in a prokaryotic host.
8. The method of claim 1, wherein said bacteriocin is selected from the group consisting of bavaricin, helveticin, acidocin, lactocin, lactacin, lacticin, nisin, leucocin, lactococcin, pediocin, curvaticin, curvacin, mutacin, mesentericin, plantaricin, streptin and sakacin.
9. The method of claim 8, wherein said bacteriocin is pediocin.
10. The method of claim 9, wherein said bacteriocin is pediocin PA-1.
11. The method of claim 10, wherein said pediocin PA-1 comprises an amino acid sequence substantially identical to the sequence set forth in SEQ ID NO: 2 or a fragment thereof.
12. The method of claim 1, wherein said bacteriocin is derived from a lactic acid bacteria species selected from the group consisting of Streptococcus spp., Lactococcus spp., Lactobacillus spp., Pediococcus spp., Leuconostoc spp., Bifidobacterium spp. and Enterococcus spp.
13. The method of claim 12, wherein said bacteriocin is derived from Pediococcus spp.
14. The method of claim 13, wherein said bacteriocin is derived from Pediococcus acidilactici.
15. The method of claim 14, wherein bacteriocin is derived from Pediococcus acidilactici PAC 1Ø
16. The method of claim 1, wherein said agent is said composition.
17. The method of claim 16, wherein said carrier is selected from the group consisting of a pharmaceutically acceptable carrier and a nutraceutically acceptable carrier.
18. The method of claim 17, wherein said carrier is a nutraceutically acceptable carrier.
19. The method of claim 18, wherein said agent is administered through an oral route.
20. The method of claim 18, wherein said composition is substantially free of contaminants from the lactic acid bacteria from which said bacteriocin is derived.
21. The method of claim 19, wherein said nutraceutically acceptable carrier is a food product.
22. The method of claim 21, wherein said food product is a fermented food product.
23. The method of claim 22, wherein said fermented food product is a fermented milk.
24. The method of claim 1, wherein said animal is a mammal.
25. The method of claim 24, wherein said mammal is a human.
26. The method of claim 1, wherein said cancer affects an organ, tissue or cell selected from the group consisting of bone, soft tissue, brain, spinal cord, breast, adrenal gland, pancreas, parathyroid, pituitary, thyroid, anus, colon, rectum, esophagus, gallbladder, stomach, liver, cervix, endometrium, uterus, fallopian tube, ovaries, vagina, vulva, larynges, oropharynges, immune cell, lung, lymph node and plasma cell.
27. The method of claim 1, wherein said cancer is lung cancer.
28. The method of claim 1, wherein said cancer is colon cancer.
29. Use of an agent selected from the group consisting of:
(a) a bacteriocin derived from a lacticacid bacteria; and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier;
for the prevention or treatment of cancer in an animal.
(a) a bacteriocin derived from a lacticacid bacteria; and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier;
for the prevention or treatment of cancer in an animal.
30. Use of an agent selected from the group consisting of:
(a) a bacteriocin derived from a lactic acid bacteria; and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier;
for the preparation of a medicament for the prevention or treatment of cancer in an animal.
(a) a bacteriocin derived from a lactic acid bacteria; and (b) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier;
for the preparation of a medicament for the prevention or treatment of cancer in an animal.
31. The use of claim 29 or 30, wherein said agent is cytotoxic to the cancerous cell of said cancer.
32. The use of any one of claims 29 to 31, wherein said agent is adapted for an administration route selected from the group consisting of intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal, intratumoral and topical.
33. The use of any one of claims 29 to 32, wherein said agent is said bacteriocin.
34. The use of claim 33, wherein said bacteriocin is substantially pure.
35. The use of claim 33 or 34, wherein said bacteriocin is a recombinant bacteriocin.
36. The use of claim 35, wherein said recombinant bacteriocin is produced in a prokaryotic host.
37. The use of any one of claims 29 to 36, wherein said bacteriocin is selected from the group consisting of bavaricin, helveticin, acidocin, lactocin, lactacin, lacticin, nisin, leucocin, lactococcin, pediocin, curvaticin, curvacin, mutacin, mesentericin, plantaricin, streptin and sakacin.
38. The use of claim 37, wherein said bacteriocin is pediocin.
39. The use of claim 38, wherein said bacteriocin is pediocin PA-1.
40. The use of claim 39, wherein said pediocin PA-1 comprises an amino acid sequence substantially identical to the sequence set forth in SEQ ID NO: 2 or a fragment thereof.
41. The use of any one of claims 29 to 36, wherein said bacteriocin is derived from a lactic acid bacteria species selected from the group consisting of Streptococcus spp., Lactococcus Spp., Lactobacillus spp., Pediococcus spp., Leuconostoc spp., Bifidobacterium spp. and Enterococcus spp.
42. The use of claim 41, wherein said bacteriocin is derived from Pediococcus spp.
43. The use of claim 42, wherein said bacteriocin is derived from Pediococcus acidilactici.
44. The use of claim 43, wherein bacteriocin is derived from Pediococcus acidilactici PAC 1Ø
45. The use of claim 29 or 30, wherein said agent is said composition.
46. The use of claim 45, wherein said carrier is selected from the group consisting of a pharmaceutically acceptable carrier and a nutraceutically acceptable carrier.
47. The use of claim 46, wherein said carrier is a nutraceutically acceptable carrier.
48. The use of claim 47, wherein said agent is adapted for an oral administration.
49. The use of claim 47 or 48, wherein said composition is substantially free of contaminants from the lactic acid bacteria from which said bacteriocin is derived.
50. The use of any one of claims 47 to 49, wherein said nutraceutically acceptable carrier is a food product.
51. The use of claim 50, wherein said food product is a fermented food product.
52. The use of claim 51, wherein said fermented food product is a fermented milk.
53. The use of any one of claims 29 to 52, wherein said animal is a mammal.
54. The use of claim 53, wherein said mammal is a human.
55. The use of any one of claims 29 to 54, wherein said cancer affects an organ, a tissue or a cell selected from the group consisting of wherein said cancer affects an organ, tissue or cell selected from the group consisting of bone, soft tissue, brain, spinal cord, breast, adrenal gland, pancreas, parathyroid, pituitary, thyroid, anus, colon, rectum, esophagus, gallbladder, stomach, liver, cervix, endometrium, uterus, fallopian tube, ovaries, vagina, vulva, larynges, oropharynges, immune cell, lung, lymph node and plasma cell.
56. The use of any one of claims 29 to 54, wherein said cancer is lung cancer.
57. The use of any one of claims 29 to 54, wherein said cancer is colon cancer.
58. A bacteriocin derived from a lactic acid bacteria for use in the prevention or treatment of cancer in an animal.
59. A composition comprising (i) a bacteriocin derived from a lactic acid bacteria and (ii) a carrier for use in the prevention or treatment of cancer in an animal.
60. A package comprising:
(a) an agent selected from the group consisting of (i) a bacteriocin derived from a lactic acid bacteria and (ii) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier; and (b) instructions for the use of said agent in the treatment or prevention of cancer in an animal.
(a) an agent selected from the group consisting of (i) a bacteriocin derived from a lactic acid bacteria and (ii) a composition comprising a bacteriocin derived from a lactic acid bacteria and a carrier; and (b) instructions for the use of said agent in the treatment or prevention of cancer in an animal.
61. The package of claim 60, wherein said agent is cytotoxic to the cancerous cell of said cancer.
62. The package of claim 60, wherein said agent is adapted for an administration route selected from the group consisting of intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal, intratumoral and topical.
63. The package of claim 60, wherein said agent is said bacteriocin.
64. The package of claim 63, wherein said bacteriocin is substantially pure.
65. The package of claim 63, wherein said bacteriocin is a recombinant bacteriocin.
66. The package of claim 65, wherein said recombinant bacteriocin is produced in a prokaryotic host.
67. The package of claim 63, wherein said bacteriocin is selected from the group consisting of bavaricin, helveticin, acidocin, lactocin, lactacin, lacticin, nisin, leucocin, lactococcin, pediocin, curvaticin, curvacin, mutacin, mesentericin, plantaricin, streptin and sakacin.
68. The package of claim 67, wherein said bacteriocin is pediocin.
69.The package of claim 68, wherein said bacteriocin is pediocin PA-1.
70. The package of claim 69, wherein said pediocin PA-1 comprises an amino acid sequence substantially identical to the sequence set forth in SEQ ID NO: 2 or a fragment thereof.
71. The package of claim 63, wherein said bacteriocin is derived from a lactic acid bacteria species selected from the group consisting of Streptococcus spp., Lactococcus spp., Lactobacillus spp., Pediococcus spp., Leuconostoc spp., Bifidobacterium spp. and Enterococcus spp.
72. The package of claim 71, wherein said bacteriocin is derived from Pediococcus spp.
73. The package of claim 72, wherein said bacteriocin is derived from Pediococcus acidilactici.
74. The package of claim 73, wherein bacteriocin is derived from Pediococcus acidilactici PAC 1Ø
75. The package of claim 74, wherein said agent is said composition.
76. The package of claim 75, wherein said carrier is selected from the group consisting of a pharmaceutically acceptable carrier and a nutraceutically acceptable carrier.
77. The package of claim 76, wherein said carrier is a nutraceutically acceptable carrier.
78. The package of claim 77, wherein said agent is adapted for an oral administration.
79. The package of claim 77, wherein said composition is substantially free of contaminants from the lactic acid bacteria from which said bacteriocin is derived.
80. The package of claim 77, wherein said nutraceutically acceptable carrier is a food product.
81. The package of claim 80, wherein said food product is a fermented food product.
82. The package of claim 81, wherein said fermented food product is a fermented milk.
83. The package of claim 60, wherein said animal is a mammal.
84. The package of claim 83, wherein said mammal is a human.
85. The package of claim 60, wherein said instructions indicate the use of said agent for the prevention or treatment of a cancer affecting an organ, tissue or cell selected from the group consisting of bone, soft tissue, brain, spinal cord, breast, adrenal gland, pancreas, parathyroid, pituitary, thyroid, anus, colon, rectum, esophagus, gallbladder, stomach, liver, cervix, endometrium, uterus, fallopian tube, ovaries, vagina, vulva, larynges, oropharynges, immune cell, lung, lymph node and plasma cell.
86. The package of claim 60, wherein said instructions indicate the use of said agent for the prevention or treatment of lung cancer.
87. The package of claim 60, wherein said instructiuons indicate the use of said agent for the prevention or treatment of colon cancer.
88. A method of inhibiting proliferation of a cancerous cell in an animal, said method comprising administering to said animal a bacteriocin derived from a lactic acid bacteria.
89. The method of claim 88, wherein said bacteriocin is substantially pure.
90. The method of claim 88, wherein said bacteriocin is a recombinant bacteriocin.
91. The method of claim 88, wherein said bacteriocin is substantially free of contaminants from the lactic acid bacteria from which said bacteriocin is derived.
92. The method of claim 88, wherein said bacteriocin is selected from the group consisting of bavaricin, helveticin, acidocin, lactocin, lactacin, lacticin, nisin, leucocin, lactococcin, pediocin, curvaticin, curvacin, mutacin, mesentericin, plantaricin, streptin and sakacin.
93. The method of claim 92, wherein said bacteriocin is pediocin.
94. The method of claim 93, wherein said bacteriocin is pediocin PA-1.
95. The method of claim 94, wherein said pediocin PA-1 comprises an amino acid sequence substantially identical to the sequence set forth in SEQ ID NO: 2 or a fragment thereof.
96. The method of claim 88, wherein said bacteriocin is derived from a lactic acid bacteria species selected from the group consisting of Streptococcus spp., Lactococcus spp., Lactobacillus spp., Pediococcus spp., Leuconostoc spp., Bifidobacterium spp. and Enterococcus spp.
97. The method of claim 96, wherein said bacteriocin is derived from Pediococcus spp.
98. The method of claim 97, wherein said bacteriocin is derived from Pediococcus acidilactici.
99. The method of claim 98, wherein bacteriocin is derived from Pediococcus acidilactici PAC 1Ø
100. The method of claim 88, wherein said animal is a mammal.
101. The method of claim 100, wherein said mammal is a human.
102. The method of claim 88, wherein said cancerous cell is located in an organ, tissue or system selected from the group consisting of bone, soft tissue, brain, spinal cord, breast, adrenal gland, pancreas, parathyroid, pituitary, thyroid, anus, colon, rectum, esophagus, gallbladder, stomach, liver, cervix, endometrium, uterus, fallopian tube, ovaries, vagina, vulva, larynges, oropharynges, immune system, lung and lymph node.
103. The method of claim 88, wherein said cancerous cells are lung cancerous cells.
104. The method of claim 88, wherein said cancerous cells are colon cancerous cells.
105. A method of inhibiting proliferation of a cancerous cell, said method comprising contacting said cell with a bacteriocin derived from a lactic acid bacteria.
106. The method of claim 105, wherein said bacteriocin is substantially pure.
107. The method of claim 105, wherein said bacteriocin is a recombinant bacteriocin.
108. The method of claim 105, wherein said bacteriocin is substantially free of contaminants from the lactic acid bacteria from which said bacteriocin is derived.
109. The method of claim 105, wherein said bacteriocin is selected from the group consisting of bavaricin, helveticin, acidocin, lactocin, lactacin, lacticin, nisin, leucocin, lactococcin, pediocin, curvaticin, curvacin, mutacin, mesentericin, plantaricin, streptin and sakacin.
110. The method of claim 109, wherein said bacteriocin is pediocin.
111. The method of claim 110, wherein said bacteriocin is pediocin PA-1.
112. The method of claim 111, wherein said pediocin PA-1 comprises an amino acid sequence substantially identical to the sequence set forth in SEQ ID NO: 2 or a fragment thereof.
113. The method of claim 105, wherein said bacteriocin is derived from a lactic acid bacteria species selected from the group consisting of Streptococcus spp., Lactococcus spp., Lactobacillus spp., Pediococcus spp., Leuconostoc spp., Bifidobacterium spp. and Enterococcus spp.
114. The method of claim 113, wherein said bacteriocin is derived from Pediococcus spp.
115. The method of claim 114, wherein said bacteriocin is derived from Pediococcus acidilactici.
116. The method of claim 115, wherein bacteriocin is derived from Pediococcus acidilactici PAC 1Ø
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002485178A CA2485178A1 (en) | 2004-11-22 | 2004-11-22 | Lactic acid bacteria-derived bacteriocin and uses thereof for prevention or treatment of cancer |
PCT/CA2005/001776 WO2006053445A1 (en) | 2004-11-22 | 2005-11-22 | Lactic acid bacteria-derived bacteriocin and uses thereof for prevention or treatment of cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002485178A CA2485178A1 (en) | 2004-11-22 | 2004-11-22 | Lactic acid bacteria-derived bacteriocin and uses thereof for prevention or treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2485178A1 true CA2485178A1 (en) | 2006-05-22 |
Family
ID=36406811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002485178A Abandoned CA2485178A1 (en) | 2004-11-22 | 2004-11-22 | Lactic acid bacteria-derived bacteriocin and uses thereof for prevention or treatment of cancer |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2485178A1 (en) |
WO (1) | WO2006053445A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012145185A1 (en) | 2011-04-09 | 2012-10-26 | Vh Biotechnology, Inc. | Bacteriocins as biocides for industrial uses |
US10195237B2 (en) | 2015-03-16 | 2019-02-05 | Imagilin Technology Llc | Compositions and methods for treating inflammatory related diseases or conditions using Pediococcus acidilactici probiotics |
US10946050B2 (en) | 2015-03-16 | 2021-03-16 | Imagilin Technology Llc | Compositions comprising probiotics and methods of use thereof |
CN116370605B (en) * | 2023-05-15 | 2023-09-12 | 山东博森医学工程技术有限公司 | Medicine for improving proliferation and phagocytic capacity of immune cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5942322A (en) * | 1982-09-01 | 1984-03-08 | Meiji Milk Prod Co Ltd | Carcinostatic agent |
-
2004
- 2004-11-22 CA CA002485178A patent/CA2485178A1/en not_active Abandoned
-
2005
- 2005-11-22 WO PCT/CA2005/001776 patent/WO2006053445A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2006053445A1 (en) | 2006-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kang et al. | The therapeutic applications of antimicrobial peptides (AMPs): a patent review | |
Ahn et al. | Pyrazole derived ultra-short antimicrobial peptidomimetics with potent anti-biofilm activity | |
Lee et al. | De novo generation of short antimicrobial peptides with simple amino acid composition | |
JP5801854B2 (en) | Antibacterial peptide | |
Liu et al. | Design of novel antimicrobial peptide dimer analogues with enhanced antimicrobial activity in vitro and in vivo by intermolecular triazole bridge strategy | |
KR102137941B1 (en) | Antimicrobial Peptide | |
AU2006231494A1 (en) | Use of RIP in treating Staphylococcus aureus infections | |
WO2017084985A1 (en) | Bacteriocin composition and method | |
Ma et al. | Expression and characterization of recombinant gallinacin-9 and gallinacin-8 in Escherichia coli | |
Mohid et al. | Combining antimicrobial peptides with nanotechnology: an emerging field in theranostics | |
KR20220026803A (en) | Antibiotic peptide with antibiotic effect on various microorganisms and antibiotics resistant bacteria | |
TW201028154A (en) | Antibiotic synergism | |
KR102286544B1 (en) | Fusion Polypeptides and Antibiotics against Gram-Negative Bacteria Comprising the Same | |
WO2006053445A1 (en) | Lactic acid bacteria-derived bacteriocin and uses thereof for prevention or treatment of cancer | |
CN112543595A (en) | Antimicrobial compositions, methods of preparation and uses thereof | |
JP6309902B2 (en) | Lantibiotics MU1140 and other lantibiotic variants with improved pharmacological and structural characteristics | |
WO2018115877A2 (en) | Compositions and methods of treatment | |
US8785399B2 (en) | Antibacterial peptides | |
US11648289B2 (en) | Antibacterial method | |
Nan et al. | Effect of disulphide bond position on salt resistance and LPS-neutralizing activity of α-helical homo-dimeric model antimicrobial peptides | |
CN102264383A (en) | Treatment of intracellular bacterial infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |